 
 
Official Title:  Emergency Department Outcomes for Patients With Opi[INVESTIGATOR_410996] : [STUDY_ID_REMOVED]  
Study Number:  19-[ZIP_CODE]  
Document Type:   Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  • January 24, 2020  
 
i  
 
 
 
 
 
NIDA CTN-0079 -A1 
Emergency Department Outcomes  
for Patients with Opi[INVESTIGATOR_2442]  
(Project ACT)  
 
Funded by: [CONTACT_175301] (NIDA)  
 
Lead Investigator: Ryan McCormack, MD, MS  
Co-Lead Investigators:  John Rotrosen, MD  and Kathryn Hawk, MD, MHS  
Co-Investigators:  Gail D’Onofrio, MD and Lisa Marsch, PhD  
 
Version  2.[ADDRESS_518357]   January 15, 20 20 
 
i Lead Investigator (LI)  Ryan McCormack, MD, MS  
 Greater NY Node  
 [LOCATION_001] University School of Medicine  
  
Co-Lead Investigators  John Rotrosen, MD  
 Greater NY Node  
 [LOCATION_001] University School of Medicine  
  
 Kathryn Hawk, MD, MHS  
 New England Consortium  
 Yale University School of Medicine  
  
Co-Investigator s Gail D’Onofrio, MD  
 New England Consortium  
 Yale University School of Medicine  
  
 Lisa Marsch, PhD  
 Northeast Node  
 Dartmouth College  
  
National Project Manager (PM)  Phoebe Gauthier, MA, MPH  
 Northeast Node  
 Dartmouth College  
  
CCTN Scientific Officer  David Liu, MD  
 National Institute on Drug Abuse  
  
Data and Statistics Center (DSC)  Paul Van Veldhuisen, PhD  
 DSC Principal Investigator  
 [CONTACT_100415], LLC  
  
Clinical Coordinating Center (CCC)  Robert Lindblad, MD  
 CCC Principal Investigator  
 [CONTACT_100415], LLC  
  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518358]   January 15, 20 20 
 
ii Protocol Development Team  
[LOCATION_001] University  Yale University  Dartmouth College  
Sarah Farkas  Gail D’Onofrio  Lisa Marsch 
Ryan McCormack  E. Jen Edelman  Phoebe Gauthier  
Patricia Novo  David Fiellin   
John Rotrosen  Kathryn Hawk   
Rebecca Shore    
Kathryn Tichy    
 
The Emmes Company, LLC  CCTN  
Brett Hart  David Liu  
Abigail Matthews  Kristen Huntley  
Caroline Mulatya   
Dagmar Salazar   
Jeremy Wolff   
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
  
 CONFIDENTIALITY STATEMENT  
This document is confidential communication. Acceptance of this document constitutes 
agreement by [CONTACT_1955][INVESTIGATOR_200560].   
NIDA CTN-0079-A1  Version 2.[ADDRESS_518359] OF ABBREVIATIONS  ........................................................................................... 1  
 STUDY SYNOPSIS ................................................................................................ ........ 3  
 Clarification of Terminology  ................................................................ .......................... 3  
 Study Synopsis  ................................................................................................ ............ 4  
 Primary Aims  ................................................................................................ ............... 4  
 Sources of Data  ................................................................................................ ........... 4  
 INTRODUCTION ................................................................................................ ............ 6  
 Preliminary Studies – Report on the CTN -0079 Parent Study  ................................ ...... 8  
 AIMS AND OBJECTIVES .............................................................................................10  
 Overarching Aim  .........................................................................................................10  
 Primary Aims  .......................................................................................................10  
 Secondary Implementation Aims  .................................................................................10  
 Secondary Effectiveness Aims  ....................................................................................10  
 Tertiary and Exploratory Aims  .....................................................................................11  
 STUDY DESIGN OVERVIEW  .......................................................................................12  
 Overview  .....................................................................................................................12  
 Table 1: Description of Study Periods Spanning CTN- [ADDRESS_518360] TIMELINE ..............................................................................18  
 Table 2: Estimated Project Timeline ............................................................................18  
 STUDY POPULATION  ..................................................................................................19  
 Qualitative Population Eligibility Criteria  ......................................................................19  
 Inclusion Criteria  ..................................................................................................19  
 Exclusion Criteria  ................................................................................................. 19 
 Full Study Population Eligibility Criteria  .......................................................................19  
 Inclusion Criteria  ..................................................................................................19  
 Exclusion Criteria  ................................................................................................. 20 
 Limited Study Population Eligibility Criteria  ................................................................. 21 
 Inclusion Criteria  ..................................................................................................21  
 Exclusion Criteria:  ................................................................................................21  
 Study Sites  .................................................................................................................21  
 STUDY OUTCOMES  .....................................................................................................22  
 Primary and Key Secondary Outcomes  ......................................................................22  
 Program Implementation (Evaluation of Clinical Program Reach)  .....................[ADDRESS_518361]   January 15, 20 20 
 
iv 
 Tertiary and Exploratory Outcomes  .............................................................................26  
 STUDY PROCEDURES  ................................................................................................27  
 Implementation Facilitation (IF)  ...................................................................................27  
 Elements of Implementation Facilitation ...............................................................27  
9
.1.1.1  External Facilitator  ............................................................................................ 27 
[IP_ADDRESS]  Local Champi[INVESTIGATOR_5458] ..............................................................................................28 
[IP_ADDRESS]  Academic Detailing ...........................................................................................28 
 Advising on ED -Initiated BUP Clinical (Non -Research) Sustainability  ..................[ADDRESS_518362] of Focus Groups/Interviews  ................................................................... 30 
 Informed Consent Procedures  .............................................................................30  
 Qualitative Data Security and Storage  ................................................................. 31 
 Qualitative Participant Incentives  .........................................................................31  
 Research Participant Procedures  ................................................................................31  
 Full Study Participants  .........................................................................................31  
9
.4.1.1  Recruitment  ......................................................................................................31 
[IP_ADDRESS]  Inform ed Consent  .............................................................................................32 
[IP_ADDRESS]  Eligibility Confirmation and Enrollment  .............................................................33 
[IP_ADDRESS]  Baseline Procedures  ........................................................................................33 
9.4.1. 5 Intervention  ......................................................................................................33 
[IP_ADDRESS]  Follow -up Visit (Day 30)  ...................................................................................34 
[IP_ADDRESS]  Participant Retention  ........................................................................................34 
[IP_ADDRESS] Premature Participant Withdrawal ....................................................................34 
[IP_ADDRESS]  Participant Reimbursement  ..............................................................................34 
 Limited Study Participants ....................................................................................34  
 RESEARCH ASSESSMENTS .......................................................................................36  
 Table 3: Schedule of Research Assessments – Full and Limited Study  ......................[ADDRESS_518363]   January 15, 20 20 
 
v 
 RESEARCH STAFF TRAINING  ....................................................................................42  
 STATISTICAL DESIGN AND ANALYSES  ....................................................................43  
 General Design  ...........................................................................................................43  
 Recruitment and Enrollment  ........................................................................................43  
 Primary and Secondary Outcomes Measures  .............................................................44  
 Definition of Primary Implementation Outcome  ....................................................44  
 Definition of Primary Effectiveness Outcome  .......................................................44  
 Secondary Outcomes Measures  ..........................................................................45  
12.
3.3.1  Secondary Implementation Outcome Measures  ...............................................45 
[IP_ADDRESS]  Secondary Effectiveness Outcome Measures  ..................................................[ADDRESS_518364] (HIPAA)  ................................[ADDRESS_518365] (DSMB)  ..........................................................64  
 Safety Monitor/Medical Monitor  ............................................................................64  
 Safety Events .......................................................................................................65  
 DATA MANAGEMENT AND PROCEDURES  ...............................................................66  
 Design and Development  ............................................................................................ 66 
 Site Responsibilities  ....................................................................................................66  
 Data Center Responsibilities  .......................................................................................66  
 Data Collection  ...........................................................................................................66  
 Data Acquisition and Entry  .......................................................................................... 66 
 Data Editing  ................................................................................................................66  
 Data Transfer/Lock  .....................................................................................................67  
 Data Training ..............................................................................................................67  
 Data Quality Assurance  ..............................................................................................67  
 PUBLICATIONS AND OTHER RIGHTS  .......................................................................68  
 PROTOCOL SIGNATURE [CONTACT_1783]  .................................................................................69  
 REFERENCES  ..............................................................................................................70  
 APPENDIX A: DATA AND SAFETY MONITORING PLAN  ..........................................[ADDRESS_518366]  
BRANY  Biomedical Research Alliance of [LOCATION_001]  
BUP Buprenorphine  
BUP-NX Buprenorphine+Naloxone (Suboxone®) 
CCC  Clinical Coordinating Center  
CCTN  Center for Clinical Trials Network  
CFR Code of Federal Regulations  
CMS  Centers for Medicare and Medicaid Services  
CoC Certificate of Confidentiality  
COWS  Clinical Opi[INVESTIGATOR_410997] -[ADDRESS_518367]   January 15, 20 20 
 
2 Abbreviation  Definition  
MDMA  Methylenedioxymethamphetamine (Ecstasy)  
ME Medical Examiner  
mg Milligrams  
MOP  Manual of Operations  
MOUD  Medication for Opi[INVESTIGATOR_410998] & Analytics Lab  
OHRP  Office for Human Research Protections  
ORCA  Organizational Readiness to Change Assessment  
OTP Opi[INVESTIGATOR_410999] (PII)  
PROMIS -29 Patient -Reported Outcomes Measurement Information System 
(PROMIS)  
QA Quality Assurance  
RE-AIM Reach, Effectiveness, Adoption, Implementation, Maintenance  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SBIRT  Screening, Brief Intervention, Referral for Treatment  
SL-BUP Sublingual buprenorphine  
THC Tetrahydrocannabinol  
TLFB  Timeline Follow -Back  
UDS  Urine Drug Screen  
XR-BUP Injectable extended -release buprenorphine  
X-Waiver  Drug Enforcement Agency  DATA [ADDRESS_518368] of terminology  used throughout this protocol , which are described  and 
defined in more detail in section 8.0 and elsewhere  in the protocol: 
• Emergency Department (ED) -initiated Buprenorphine (BUP)  clinical program  refers to 
all the components of clinical care required to initiate treatment with BUP to ED 
patients with opi[INVESTIGATOR_2427] (OUD) and provide them with access to ongoing 
treatment through referral.  Site-specific clinical protocols were introduced in and by 
[CONTACT_108440]/ED during the parent CTN -[ADDRESS_518369] matter expertise and other Implementation Facilitation (IF) activities . Each 
site-specific clinical protocol provides clinical guidance related to assessing a patient’s  
“eligibility and willingness” to receive ED -initiated BUP (screening/identif ication followed 
by [CONTACT_411060] ) and the other critical actions to treatment initiation and referral . 
• ED-initiated BUP  refers to BUP administered and/or prescribed to an ED patient as 
part of the ED visit . Referral to ongoing treatment should be provided to all patients 
receiving BUP treatment initiation.  
• ED-expedited BUP  refers to a patient being transferred directly or provided with 
specific “warm hand off” of care to a treatment setting or provider capable of 
prescribing or administering BUP within [ADDRESS_518370] 
BUP treatment initiation is a means of providing expedited access to treatment for 
patients who are candidates for ED -initiated  BUP but who are not in sufficient 
withdrawal to administer BUP  and/or  when there may or may not be a provider who 
has the DEA DATA 2000 “X -wavier” licensure required to prescribe BUP . 
• ED-initiated /expedited BUP  (abbreviation for “ ED-initiated  BUP and/or ED -expedited 
BUP ”) refers to a composite measure of either ED -initiated BUP and/or ED -
expedited BUP occurring.  
• Candidate for ED -initiated BUP  refers to an individual who is documented or 
presumed (based on available data) to be clinically appropriate to be started on BUP 
treatment for OUD during the ED visit  via either ED -initiated BUP or ED -expedited 
BUP . This terminology will be used in place of the term “ eligible and willing  to 
receive ED -initiated BUP ” that was used in the parent CTN -0079 study.  Although the 
terms are essentially synonymous, this change will help distinguish patients who 
meet inclusion criteria for the clinical intervention (ED -initiated/  expedited BUP) from 
those who meet the additional criteria for research participation. In addition to changing the terminology/nomenclature,  we have amended the operational 
definition and  methods of determining candidacy for ED -initiated BUP for this study 
by [CONTACT_411061] . The clinical documentation 
requirements to meet criteria of “candidate” are less stringent than was required in 
the parent study to be “eligible and willing” and are further described in section 8.1. 
In other words, all patients who would have met the CTN -0079 parent study criteria 
of “eligible and willing to receive ED -initiated BUP” will also meet criteria to be a 
“candidate for ED-initiated BUP.” Also of note, any patient who meets the criteria to 
be a candidate for ED -initiated BUP is also a  candidate for ED -expedited BUP.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518371]   January 15, 20 20 
 
4 
 Study Synopsis  
CTN -0079- A1 will evaluate the extent of diffusion and the sustainability of the Emergency 
Department ( ED)-initiated buprenorphine ( BUP ) clinical programs  (inclu sive of opi[INVESTIGATOR_2428] [ OUD] screening, BUP  treatment initiation, and referral for treatment ) introduced at 
each of the three clinical sites in the parent CTN -0079 study in furtherance of our original 
overarching research question:  In settings with high need, limited resources, and differing 
staffing structures for managing OUD, what is the feasibility and impact of introducing a 
clinical protocol for OUD screening and BUP treatment initiation in the ED with referral for 
treatment ? CTN-0079 -A1 (the “ancillary study”)  is an implementation study that will use mixed 
methods and triangulate multiple sources of data to evaluate the feasibility, acceptability, 
sustainability, and impact of the ED- initiated BUP clinical program and implementation facilitation 
strategy and identify factors influencing diffusion and effectiveness.  
 Primary Aims  
1. Program Implementation  (Evaluation of Clinical Program Reach):  Over the course of 
the CTN -0079- A1 study, to estimate the proportion of  patients  receiving (i) ED-
initiated/expedited BUP (primary analysis) and (ii) ED-initiated  BUP  (secondary 
analysis) amongst ED  patients who are candidates for ED -initiated BUP . The 
composite ED -initiated/expedited BUP measure will be analyzed primarily; ED -
initiated BUP will b e evaluated secondarily.  
2. Program Effectiveness:  Amongst participants who received ED -initiated /expedited  
BUP  over the course of the CTN -0079- A1 study , to estimate the proportion of 
participants : (i) with confirmed linkage to formal addiction treatment  for OUD within 
one week , and (ii) who are confirmed to be engaged in formal addiction  treatment 
for OUD on the 30th day following ED discharge . Engagement in treatment on the 30th 
day following ED discharge  will be analyzed primarily; linkage will be evaluated 
secondarily.  
Other Aims : We will also conduct several secondary implementation and effectiveness analyses 
as well as tertiary and exploratory analyses that include periods within the parent and ancillary studies and comparing available sources of data to further develop quality measures.  
 Sources o f Data 
1. Health record, administrative, claims, and registry data 
2. Research assessments involving ED patients who are candidates for ED-initiated BUP 
for OUD; these assessments will document the index ED visit through the 30th day 
following ED discharge  
3. Qualitative data (qualitative interviews, focus groups, field notes) involving ED staff, ED 
patients, and other stakeholders and key informants  
4. Data collected through the CTN-0079 parent study  
5. Qualitative data collected through CTN- 0069  
As in the parent study , CTN -0079 , all clinical care  (BUP and referral) will be delivered as part of 
each facility’s  clinical protocol, rather than as a research procedure.  Implementation Facilitation 
(IF) activities will continue during ancillary trial preparation with a more intensive booster of IF 
activities occurring in the last month prior to trial commencement. Thereafter, all study IF support 
will cease and ancillary study data collection will begin. Data collection will occur over  a course of 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518372]   January 15, 20 20 
 
5 approximately 12 months , divided into  two 6-month study periods  – the Post-IF and Maintenance 
Periods. In accordance with the RE-AIM framework  (Reach, Effectiveness, Adoption, 
Implementation, Maintenance) , at minimum, a period of at least [ADDRESS_518373] been adapted from those used in the parent study to incorporate lessons learned. Thus, primary outcome analyses will use data from the ancillary 
study alone. Tertiary and exploratory analyses will incorporate data from the 6 -month period of 
patient enrollment of the parent study – i.e., the IF Period – as well as  data derived from linkage 
to administrative databases  extending over a longer timeframe (from 1 year prior to 
patient/participants’ ED visit to 2 years following the ED visit/ enrollment).  
ED patients who are candidates for ED -initiated BUP (and who meet the additional study eligibility 
criteria  to become research parti cipants ) may be enrolled as Full Study or Limited Study 
participants. Full S tudy participation involves two in- person research visits  occurring ideally at the 
index ED visit and 30  days after ED discharge , as in the parent study. In addition, consenting 
participants will be asked to authorize study staff to perform a data match with health and 
administrative data pending data use agreements for a period beginning 1 year prior to study 
enrollment and ending 2 years following study enrollment . Limite d Study p articipation will be 
offered to candidates who meet criteria for ED -BUP candidacy but do not meet all of the eligibility 
criteria (e.g., inadequate locator information) for Full Study participation. Limited S tudy 
participation  includes  completion of screening assessments and data matching only, without 
active participation in the baseline and day 30 research visits . In addition, a Waiver of 
Consent /HIPAA Authorization  is requested to perform data matching for all adult ED patients who 
screen positive for non- medical opi[INVESTIGATOR_411000]. Analyses will 
also be conducted for subgroups, including those determined to be candidates for BUP and/or 
receive medication for OUD, among others . 
We will also recruit ED st aff, patients, and other stakeholders  and key informants to be participa nts 
in qualitative interviews and/or focus groups  at the close of study for the purpose of learning about 
patient -, provider -, and organizational -level barriers and facilitators to adoption and sustainability. 
These data (along with qualitative data collected through CTN -0069 and CTN -0079) will provide 
context to study outcomes and allow us to more comprehensively address our primary research 
question.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518374]   January 15, 20 20 
 
6 
 INTRODUCTION 
The opi[INVESTIGATOR_15817] c ontinues to ravage the country. ED visits for opi[INVESTIGATOR_411001] 30% in the brief period from July 2016 through September of 2017 in the United 
States ( US).[1] A recent analysis of over 17,000 opi[INVESTIGATOR_411002] a 5% annual 
mortality rate and that only one in three received opi[INVESTIGATOR_411003].[2] All-cause and opi[INVESTIGATOR_2480]- related mortality were reduced by 59% among patients who received 
agonist treatment. [2] It is imperative to maximize linkage to evidence- based care for OUD from 
less traditional settings such as the ED. Through a 3- arm randomized trial of 329 opi[INVESTIGATOR_411004], D’Onofrio et al. demonstrated ED -initiated BUP with referral for ongoing BUP is superior 
to referral alone in engaging patients with OUD at [ADDRESS_518375] effective.[3, 4]  Despi[INVESTIGATOR_6831], 
few EDs have adopted this intervention. Although there appears to be momentum to address 
OUD in the ED, logistical barriers exist in translating research into practice. [5] 
Through the NIDA CTN -0069 ( Project ED Health ) and CTN -0079 (ED -CONNECT) studies, we 
have gained invaluable knowledge about strategies to facilitate BUP initiation in the ED by 
[CONTACT_411062] a total of 7 geographically diverse, academic , 
and community EDs serving urban and rural communities with differing levels of resources to tr eat 
OUD. CTN- 0079, a multicenter implementation feasibility study, was born out of the need for 
timely intervention, designed to balance scientific rigor with the public health need for rapid dissemination of evidence and strategies to effectively implement BUP in EDs that are representative of where the majority of people receive care. It complements CTN -0069, a Hybrid 
Type 3 Effectiveness -Implementation study [6] examining the effect of IF on ED provider uptake 
of BUP and the effect of IF on patients’ engagement in treatment in four large, urban, academic 
EDs.  
Although the rapid timeline of CTN -0079 was of critical import, the brief period of study is not 
adequate to study the extent to which diffusion of the ED -initiated BUP innovation (clinical 
program) will occur – as time is a main element of all diffusion research. Most innovations have 
an S -Shaped rate of adoption with the slope of the “S” varying from innovation to innovation, 
across different settings, and because of a number of other potential factors. [7] For example, the 
curves shown in Figure 1 could represent the rate of adoption of ED -initiated BUP in different EDs 
and/or when different implementation strategies are employed.  
 
 
Figure 1: From Diffusion of Innovations  

NIDA CTN-0079-A1  Version 2.[ADDRESS_518376]   January 15, 20 20 
 
7 Prior to CTN -0079, patients presenting with OUD  to its three clinical sites were not offered ED-
initiated BUP. In addition to training the staff, policies, documentation templates, referral networks, 
and other processes needed to be developed and approved prior to implementation. Norms and 
system- level qualities of each context as well as the opi[INVESTIGATOR_411005] – both 
supporting and opposing the intervention – have differentially impacted diffusion. Throughout 
implementation, sites have iteratively modified the ED -initiated BUP innovation to be ac ceptable 
to the provider s and to staff adopters and suit the broader local context. By [CONTACT_411063], we 
anticipate that we will have provided adequate external facilitation for meaningful adoption to take place. However, it is likely that diffusion will be somewhere in the take -off period (Figure 1) by 
[CONTACT_411063], and thus, we will not know the full extent to which adoption will occur. Nor will we be 
able to report on sustainability or the factors influencing these outcomes.  
Building on the existing infrastructure of the CTN -0079  parent s tudy, this ancillary study will 
evaluate the diffusion and sustainability of the ED -initiated BUP clinical programs introduced 
through the parent study. This study remains well aligned with our initial overarching research 
question : In settings with high need, limited resources, and differing staffing structures for 
managing OUD, what is the feasibility and impact of introducing a clinical protocol for OUD 
screening and BUP treatment initiation in the ED with referral for treatment?  
To accomplish this, and specifically assess sustainability at the patient, provider, and 
programmatic levels, we will incorporate elements of the RE -AIM framework .[8, 9]  First, there will 
be an initial brief Implementation Facilitation (IF) booster of external facilitation to help prepare 
sites for their transition to independence (designate personnel, etc.) and ensure that processes 
are in place to allow us to collect the data we need with minimal influence on clinical activities. 
Thereafter, all study supported IF activities will cease. Next, using a clinical protocol adapted from 
CTN- 0079, programmatic evaluation and patient enrollment will be extended to monitor diffusion 
trends and effectiveness outcomes for the next 12 months; the first six months being the post -IF 
period followed by [CONTACT_411064] (in accordance with the RE -AIM framework). 
We will use a mixed methods approach combining quantitative and qualitative inquiry with administrative and health record data. Qualitative inquiry of key informants (i.e., ED staff, 
stakeholders, patients) will occur at  study close (rather than throughout patient enrollment) to 
minimize the potential influence on the natural course of clinical actions beyond the IF period.  
Lastly, in this early stage of programmatic adoption, the maintenance and growth of this clinical program will be vulnerable, particularly without ongoing support. As such, we have included an 
interim analysis and contingency plan to identify and respond accordingly should the program fail 
to be sustained (See section 5.4). 
Our overarching aim is: Using mixed methods and triangulating multiple sources of data 
collected over the course of the parent and ancillary studies, to evaluate the feasibility, 
acceptability, sustainability, and impact of the ED- initiated BUP clinical program and IF strategy 
and identify factors influencing diffusion and effectiveness.  For our primary analyses, we will 
evaluate program implementation via reach ( i.e., proportion of candidates receiving ED -
initiated /expedited BUP) and program effectiveness ( i.e., proportion successfully linked to and 
engaged in OUD treatment). We will also conduct several secondary implementation and 
effectiveness analyses as well as tertiary and exploratory analyses . 
Significance: It is imperative to maximize linkage to evidence- based care for OUD from less 
traditional settings such as the ED. It has been more than 3 years since D’Onofrio et al.’s landmark 
trial demonstrated the feasibility, safety, and efficacy of initiating treatment with BUP in the ED 
and, despi[INVESTIGATOR_040] a highly visible opi[INVESTIGATOR_15817], few EDs have adopted this life -saving 
intervention. [3] Currently, EDs are ill- equipped to respond. Developi[INVESTIGATOR_411006], BUP treatment initiation, and facilitated referral that is 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518377]   January 15, 20 20 
 
8 practical for the ED as well as a pragmatic implementation strategy is critically needed. The RE -
AIM framework allows the needed multi -level analysis of whether this efficacious treatment can 
be widely adopted and translated into meaningful outcomes in this real -world complex 
environment .[8, 9]  
Innovation: The integration of systematic screening, BUP treatment initiation, and facilitated 
referral for treatment of OUD into the clinical workflow of the ED is an innovative strategy to 
expand access to life- saving treatment for patients with OUD. Also, it is innovative to introduce 
and to study this novel intervention in settings with high need, limited resources, and differing 
staffing structures for managing OUD, rather than focusing solely on the large academic centers 
where research is more often conducted. Further, we are efficiently leveraging resources, materials, and learning across these and other studies. Several design aspects are innovative 
and address existing gaps and criticisms of prior study . Study participation at the setting or staff 
level, on maintenance or sustainability, and costs, are consistently underreported in the RE -AIM 
literature and have been emphasized as needing attention. [9, 10]  There is also an increased 
appreciation for the importance of context and the need for qualitative measures to help 
understand RE- AIM results .[9] Including these components in our study, and importantly, without 
interfering with the clinical workflow – minimizing the likelihood of contaminating outcomes – is 
innovative and will improve reporting on key issues related to implementation and external 
validity. [10] 
 Preliminary Studies – Report o n the CTN-0079 Parent Study  
The CTN-0079 parent study has been highly successful in achieving our overarching objectives. 
This expansion concept is the natural extension of our team’s efforts to develop and accelerate 
the implementation and dissemination of best practices for treatment of OUD in general medical 
settings and will efficie ntly and expeditiously leverage the existing physical and intellectual 
infrastructure of CTN -0079.  
Using a rigorous mixed methods and participatory action approach well -founded in 
implementation science, we have gained perspectives of patients, ED and community treatment providers, staff, and key stakeholders. In addition to the expected challenges, we encountered 
several unanticipated barriers and delays, including that all sites announced changes to their EMR 
systems during the study. One site changed ED staffing agencies (such that all ED providers were new), had a written policy precluding the use of BUP by [CONTACT_175302], and required Catholic Church 
board approvals for policies.  Despi[INVESTIGATOR_411007], a clinical protocol for  screening, 
BUP treatment initiation, and referral has been implemented at each site with adoption by [CONTACT_411065].  
Our team has elicited a wealth of qualitative data while encountering the considerable barriers 
and facilitators associated with these heterogeneous contexts. We have been “on the ground” in 
the EDs to conduct trainings and to develop, evaluate, and iteratively refine individual - and 
systems- level implementation plans. The effor t required to address barriers, develop and provide 
education/training, and to develop clinical protocols and related components has required more investigator effort and external facilitation than anticipated. Although this degree of effort may 
seem to point towards this program not being feasi ble, our effort has resulted in considerable 
translatable knowledge and the development of resources to support broader implementation.  
We have developed clinical protocols, bedside guides, EHR templates, and various training materials to support implementation and have begun to make them available online at 
http://www.drugabuse.gov/ed- buprenorphine
 and are working with the American College of 
Emergency Physicians (ACEP), the largest emergency medicine organization, to develop a toolkit 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518378] recently, our work has 
gained international attention through publication in the New England Journal of Medicine. [5] 
During the drafting of this protocol, recruitment for the parent study closed. Data lock recently  
occurred for formal analyses and reporting. The number of patients who received ED-initiated 
BUP has surpassed our original estimates. Importantly, without study intervention, the number of 
patients receiving BUP would be zero. Prior to CTN- 0079, none of its clinical sites offered ED -
initiated /expedited BUP or even formal processes to identify patients with non- medi cal opi[INVESTIGATOR_2441].  
For the main secondary outcome of engagement in treatment at [ADDRESS_518379] identified and addressed 
several factors contributing to recruitment challenges. For example, we expanded our operating definition of “eligible and willing to receive ED -initiated BUP” to include patients for whom these 
criteria could be inferred reasonably through such documentation in the patient’s medical record  
to address the aforementioned differences in clinical and research terminology.  In this new study, 
we will incor porate these and other lessons learned, which should boost enrollment and the 
completeness and quality of data capture . 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518380] of the ED- initiated BUP clinical program and implementation  facilitation strategy and 
identify factors influencing diffusion and effectiveness.  
 Primary Aims  
1. Program Implementation (Evaluation of Clinical Program Reach):  Over the course of 
the CTN -0079- A1 study, to estimate the proportion of  ED patients  receiving (i) ED-
initiated/expedited BUP and (ii) ED-initiated BUP treatment amongst ED patients 
who are candidates for ED -initiated BUP. The composite ED -initiated/expedited 
measure will be analyzed primarily; ED -initiated BUP will be evaluated secondaril y. 
2. Program Effectiveness : Amongst participants who received ED- initiated /expedited BUP 
a. To estimate the proportion of participants with confirmed linkage to formal addiction treatment  for OUD  within one week following ED discharge 
(operationalized as within 7 -10 days) ; 
b. To estimate the proportion of participants who are confirmed to be engaged in 
formal addiction treatment for OUD on the 30
th day following ED discharge . 
Engagement in treatment on day 30 will be analyzed primarily; linkage will be 
evaluated secondarily.  
 Secondary Implementation Aims  
1. To estimate the rates of ED-initiated/expedited BUP provided via the ED over the 
course of the CTN -[ADDRESS_518381] -IF and Maintenance 
Periods , including each time BUP is provided and BUP provision among unique 
individuals among denominators of 30 -day and 6 -month periods of time; 
2. To gen erate diffusion curves in which the number of patients provided BUP is displayed 
graphically as a function of time (30-day periods) . 
3. To evaluate provider adoption as measured by [CONTACT_411066]: (a) provided BUP treatment and (b) completed DATA 2000 
training  to become a BUP prescriber. 
4. To generate proportions for the completion of critical actions and other components of the ED -initiated BUP clinical program . 
 Secondary Effectiveness Aims  
1. To evaluate patient -level outcomes 30 days after ED discharge and changes from pre-IF 
among CTN -0079- A1 study participants who received ED-initiated/expedited BUP , 
including non- medical opi[INVESTIGATOR_74480] (self -report using TLFB; urine toxicology), 
healthcare utilization, quality of life, and other patient -reported outcomes ( PROMIS -29, 
PHQ -9, T reatment Effectiveness Assessment (TEA), treatment  satisfaction, risk 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518382]   January 15, 20 20 
 
11 behaviors, overdose events, and other drug- related consequences).  
a. Secondary analyses will evaluate the participant subgroups who received ED -
initiated BUP and ED -expedited BUP separately as well as those who did not 
receive BUP.  
All the above secondary effectives analyses will b e performed for Full Study participants . 
Additional secondary analyses for  limited study participants will be performed for available 
effectiveness outcome measures , as listed in the table of assessments.  
 Tertiary and Exploratory Aims  
1. To evaluate implementation and effectiveness outcomes over the course of t he CTN -[ADDRESS_518383] comparisons between each of the 
defined 6- month Implementation (i.e., p arent study), Post -IF, and Maintenance Periods 
for which comparable data exists.  
2. To further develop meaningful quality  measures  related to the recognition and 
treatment of OUD in the ED to support data harmonization and the use of valid, 
reliable, comprehensive, and useable measures in  future research and clinical 
performance monitoring and standards by:  
a. Testing permutations of the implementation and effectiveness outcomes, 
by: 
i. Evaluating permutations of how the numerator and denominator are defined and how these  data are collected for the primary 
implementation outcome ;  
ii. 
Evaluating different timeframes of assessment (e.g., 72 hours, 14 days ) 
and including  a time -to-event for the primary effectiveness outcomes ( i.e., 
linkage to and engagement in treatment), and exploring alternate means of how these data are captured and defined (e.g., claims and other 
administrative data) .
 
b. Comparing  the agreement of quality measures assessed using 
administrative data to the gold standard data collected through the clinical 
trial research assessments.  
c. Identify ing patient -level characteristics as well as structural and process 
measures associated with measure completion and effectiveness.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518384]   January 15, 20 20 
 
12 
 STUDY DESIGN  OVERVIEW 
 Overview  
The ancillary study will use mixed- methods combining quantitative and qualitative inquiry 
(interviews/focus groups and field notes) with administrative and health record data with some 
analyses including data collected from the parent CTN -0079 study. Further, qualitative data will 
be analyzed in the context of themes derived from CTN- 0069 and CTN -0079.  CTN-0079 -A1 is 
planned to be conducted at the same three  sites of the parent study: (1) Catholic Medical Center, 
Manchester, NH; (2) Valley Regional H ealthcare , Claremont, NH; (3) Bellevue/NYC Health and 
Hospi[INVESTIGATOR_600], [LOCATION_001], NY. Many of the methods, operating procedures, measures and forms will 
be retained or adapted from the parent study. However, CTN- [ADDRESS_518385] and associated 
records . Also, we enrolled participant s who were determined to be eligible for and willing to 
receive ED -initiated BUP (both those who received BUP and those who did not) to participate in 
assessments following their index ED visit to explore patient -level outcomes and learn about 
barriers and facilitators encountered during or associated with their actual experience in the ED.  
In the ancillary study, there will be t hree phases of participation: 1) candidates for ED-initiated 
BUP will be enrolled over a 12 -month period to  participate in two research visits (Days 0 and 30) 
and/or authorize administrative data matching, 2) ED staff, patients, and stakeholders w ill 
participate in semi- structured qualitative interviews/focus groups at study close, and 3) 
retrospective chart review and data matching for all adult ED patients identified to have non-medical opi[INVESTIGATOR_411008], Post -IF or Maintenance periods . The study 
will be conceptualized using the RE -AIM framework . 
As the parent study comes to a close and while we finalize preparations for the ancillary study 
(e.g., obtain regulatory approvals, finalize data collection procedures, etc.), we will synthesize the 
quantitative and qualitative data collected thus far, identify existing needs, and develop and 
execute a plan to support implementation and sustainability at the sites. The final month of this IF 
period (the IF “booster”) will involv e more intensive external facilitation. This IF booster will mark 
the end of study intervention/support and the end of the IF Period and the beginning of the ancillary study. At that time, data collection for the primary outcome and participant  enrollment 
will begin and continue for a period of 12 months divided into two 6- month periods – Post-IF and 
Maintenance Periods. The Post -IF and Maintenance Periods are identical in terms of study 
activities. They are differentiated only by [CONTACT_941] 6- month minimum interv al of time following the 
cessation of study support that must pass to evaluate maintenance or sustainability in accordance with the RE -AIM framework. Upon completion of 12 months of participant  enrollment, we will 
recruit ED staff, patients, and other stakeholders and key informants to participate in qualitative 
interviews and/or focus groups at the close of study for the purpose of learning about patient -, 
provider -, and organizational- level barriers and facilitators to implementation and sustainability. 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518386]   January 15, 20 20 
 
13 These data (along with qualitative data collected through CTN -0069 and CTN -0079) will provide 
context to study outcomes and allow us to more comprehensively address our primary research 
question.  
 Table 1: Description of Study Periods Spanning CTN -0079 and 
CTN-0079- A1 
 
Period  Study  Description  
Pre-
Implementation 
Period  CTN -0079  Preceded CTN -0079 data collection and ended upon approval of 
ED-initiated BUP clinical pr otocols at the clinical sites. During this 
time, BUP was not initiated in the ED sites  (to any meaningful 
extent) and participants were not enrolled (except for qualitative 
inquiry).  
Implementation 
Period (IF Period)  CTN -0079 to 
CTN -0079- A1 
(all enrollment 
during parent 
study ) Initial period of program adoption – when clinical protocols were 
first approved and introduced at ED sites and supported by [CONTACT_3449] -
supported IF – and will extend into CTN -0079- A1. This period 
marked the beginning of the 6 -month period of data collection  for 
the parent study (10/2018 - 5/2019). Limited IF activities will 
continue after the parent study as CTN -0079- A1 preparations are 
finalized and approved. Post IRB -approval, a one-month  intensive 
IF Booster will mark the end of all study supported intervention/IF 
and the IF Period.   
Post -IF Period  CTN -[ADDRESS_518387] close -out qualitative interviews and focus 
groups with ED staff , patients,  and stakeholders , provide/receive 
feedback, and provide final IF.  
Note: If IF activities are resumed due to failure of t he ED -initiated 
BUP clinical program to be maintained, by [CONTACT_108], this will no longer constitute a Maintenance Period (as described in the Contingency Plan, section 5.4).
 
 
 Study Procedures Overview  
As in the CTN -0079  parent study , all clinical actions of the ED -initiated BUP clinical program , 
including screening, assessment, medication initiation, and referral for ongoing treatment, 
will be delivered as a clinical procedure, rather than by [CONTACT_5051]. Consenting 
patients who are candidates for ED -initiated BUP who meet additional eligibility criteria (s ee 
section 7.2 and 7.3) will be recruited by [CONTACT_411067] ; 
ideally, the first will occur during the index ED visit and the second will occur on the 30th day 
following ED discharge . Consenting Full Study participants will also be asked to authorize study 
staff to perform a match with health and administrative data to further assess implementation and 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518388] 
study  enrollment . All Full Study participants will be required to participate in data matching; 
however , they will have the opportunity to opt out of releasing retrospective data prior to study 
enrollment . Limited Study participation will be offered to ED -BUP candidates who do not meet all 
eligibility criteria for Full Study participation (e.g., inadequate locator information; unwilling to 
participate in research visits).  Limited Study participation will be  limited to data matching only 
without active participation in the baseline and day 30 research visit s. The clinical care of patients 
enrolled in either the Full or Limited  Study will not be affected.  
Candida cy for ED -initiated BUP  will serve as the initial criteria for determining a patient’s 
potential study eligibility , as well as for  the denominator of the primary implementation 
outcome. This terminology differs from the terminology  of “eligible and willing to receive ED -
initiated BUP”  used in the parent study for the aforementioned reasons and lessons  learned 
through the parent  study.  In brief, any patient who would have met the  eligibility criter ia as 
defined in the parent study will be eligible in the ancillary study as will patients identified to 
have nonmedical opi[INVESTIGATOR_411009].  To be eligible for research participation,  all criteria used to determine one ’s 
eligibility  and willing ness to receive ED -initiated BUP must be s atisfied as confirmed through 
research staff assessments  or sufficient EMR documentation . The eligibility criteria are 
discussed in greater detail  in sections 7.[ADDRESS_518389] abstraction procedures used in CTN -0079 . 
In addition, u sing methods adapted from CTN -0069 , research staff will identify potential 
participants by [CONTACT_411068] y via conducting  health survey s. (Study entry 
procedures are discussed further in s ection 9.0.) The ED Health Survey has questions related 
to eligibility  (for both ED -initiated BUP and study participation) embedded within  general 
public health screening qu estions . Although this research assessment (the ED Health 
Survey) will be used primarily for recruitment purposes, all p atients with OUD identified 
through this research assessment  will be given an informational pamphlet . This minimal 
clinical intervention (health quiz and pamphlet) is unlikely to have a substantive effect on 
outcomes or to  influence clinical procedures associated with the delivery of the ED-initiated 
BUP progr am. Importantly, research staff will not commun icate responses to the ED Health 
Survey  to clinical staff . The study purpose will be described as a study to evaluate outcomes 
among ED patients with OUD (s ection 12 .0). 
 Contingency Plan  
If we conclusively determine that the ED-initiated BUP program is not  sustained at one or more 
ED sites via interim analysis, we will declare this outcome (i.e., failed sustainability). Rather than 
ending the study at this point for the affected site(s)  and/or observing the continued failure, we 
will use this as an opportunity to learn about why the failure occurred  and attempt to restore 
programmatic adoption.  Investigators will return to the sites to conduct interim focus groups and/or 
interviews and IF activities will resume (i.e., a second IF booster). P articipant enrollment and data 
collection will continue throughout the planned study timeline. By [CONTACT_108], site(s) receiving additional support will no longer enter or be in the Maintenance Period a nd will not be considered 
for outcomes involving sustainability and maintenance but  may be considered for some 
exploratory outcomes. Statistical analyses and reporting would be amended accordingly with appropriate sensitivity analyses.  We decided to include this contingency plan given the gravity of 
the epi[INVESTIGATOR_411010].  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518390] -IF Period to 
determine if the study should proceed at each site as planned – without additional IF support – 
into the Maintenance Period. For this analysis, we will compare the rat e of ED -initiated BUP during 
the 6- month periods of enrollment occurring during the IF Period of the parent study and the Post -
IF period of the ancillary study (i.e., the number of patients receiving ED -initiated BUP divided by 
a denominator of 6 months). Note that this calculation is based on medical record abstraction, 
and not assessment data collected from enrolled participants. For this analysis, the ED -initiated 
BUP measure will include ED -initiated BUP ( administered or prescribed) without inclusion of  ED-
expedited BUP (warm handoffs to BUP treatment within 24 hours), as data for the later measure 
was not formally collected in the parent study.  Sustainability at the site will be declared to have 
failed if the treatment initiation rate in the Post -IF per iod is <25% of that observed during the IF 
Period, with the qualification that ED-expedited BUP does  not become a primary means of 
treatment for a site, such that inclusion of this outcome would significantly affect the analysis and 
change the conclusion.  
 Data Matching and Linkage to Administrative Data  
Administrative data refers to information that is collected, processed, and stored in automated 
information systems. Administrative data include medical plan enrollment or eligibility information, 
claims in formation, and managed care encounters. The claims and encounters may be for 
hospi[INVESTIGATOR_411011], professional services, prescription drug services, laboratory services, etc. [11]  
Using administrative records data and survey/participant data to enhance each other offers 
enormous potential for scientific and policy -related research. The improved availability of data 
sources and progress in data- matching technology have expanded the potential for creating such 
linked data. Provision of administrative data for scientific research reflects a cost -effective way of 
complementing the primary study data as these data are already being collected for administrative 
purposes. Linking administrative records data with participant level assessment data helps to 
overcome the shortcomings of administrative data by [CONTACT_411069]. [12]  
Unfortunately, the current clinical data research infrastructure does not allow for leveraging 
existing data streams accurately. Fragmented health systems, the lack of interoperability between clinical and research systems, and need for EHR phenotypes that better characterize patients 
with opi[INVESTIGATOR_2480] -related presentations are among the current barriers.  The value of EMR data to track 
ED patient activity is further compounded by [CONTACT_49392], unlike most other clinical settings, continuity of care with a provider or within a health care system is not expected for ED patients. 
Further, there are added privacy concerns and restrictions accessing substance use dat a. That 
being said, members of our team are involved in CTN -[ADDRESS_518391] a data  set of patient data  to permit linkage to administrative data 
for the purpose of  quality  measurement and performance monitoring that is more feasible and 
sustainable (less labor intense) for broader generalization. Included in this data matching will be 
patients who enroll in either the Full or Limited Study as well as all adult ED patients  screening 
positive  for non- medical opi[INVESTIGATOR_411012] -IF and Maintenance periods  for whom there 
is adequate identifying information available to permit matching . Similarly , we will draw on the 
data set generated for  patients who presented during CTN-[ADDRESS_518392] a Waiver of 
Consent /HIPAA Authorization to access this patient information.  
Administrative data matching will allow us to evaluate outcomes for the larger population of 
patients who present to the ED with OUD.  It is essential to evaluate the entire population of 
patients with opi[INVESTIGATOR_411013].  For several reasons, many of the most at -risk 
individuals who are less likely to access health services are also less likely to become research 
participants (e.g., those who lack phone access or home address, lack social contacts for locators, 
or who present the ED overnight or outside of conventional business hours).  Therefore, these 
subgroups are not equitably represented in the research and may not expect the same potential 
future benefits that result from it.  This administrative data match  conducted through a  waiver of 
consent will mitigate this problem. As we have learned in CTN -[ADDRESS_518393] the large volume of patients treated in the ED to obtain individual 
authorizations, particularly among the aforementioned individuals without stable phone access or addresses.  Through a waiver of consent and in accordance with safeguards to be outlined in 
pending data use agreements, we will share a data set with the covered entity that is the 
owner/custodian of the administrative data. This effort  is well- aligned with our overall goal to 
inform the development and improve the effectiveness and reach of programs that identify and initiate treatment of OUD in EDs in a way that is generalizable to support population- level health 
quality improvement and treatment outcomes.  
One way that we will leverage existing data streams will be to compare the data collect ed through 
participant enrollment to the data capture that would have been possible had we not enrolled patients (other than to obtain their authorization health record and administrative data review).  
For example, we will review the prescription drug monitoring program (PDMP) database to 
determine if and when patients/participants filled a prescription for BUP following their index ED 
visit. This example also demonstrates the shortcomings of relying on individual sources of data, 
as the PDMP does not include medication administration in an Opi[INVESTIGATOR_361022] (OTP) 
or inpatient settings. Thus, this work is exploratory and will help inform the development of future studies and quality measures.  
Data of particular interest : Means of collecting data related to h ealth services utilization (ED visits, 
hospi[INVESTIGATOR_602], ambulance use, as well as associated costs), inc lude through the EM R and 
linked EMR data, direct contact [CONTACT_361179], health claims data, Fire Department and 
Emergency Medical Services (EMS) databases, state drug and alcohol treatment services 
databases, and other sources. We wil l also explore means of c onfirming subsequent OUD 
treatment and receipt of MOUD, including though the use of the PDMP, claims, and state  drug 
and alcohol treatment services databases.  Other data of interest include, but are not limited to , 
state vital statistics data and Medical Examiner ’s data (overdose- and all -cause mortality), law 
enforcement databases (arrests/incarcerations), EMS data (ambulance use and overdose 
events).  These administrative data would also inform potential cost analyses. 
In both New Hampshire and [LOCATION_001], there are ongoing efforts  to create an integrated data 
warehouse and data analytics platform. These systems allow for data from disparate data 
systems in their respective states to be integrated into a common data framework . The New 
Hampshire  data systems include 25 data  sets, including All Payer Claims Data (APCD) and other 
health data, Department of Health and Human Services (DHHS), and law enforcement data . 
Similarly, the NYC system will integrate a wide array of state government data datasets . Our team 
will work with relevant stakeholders  with a focus on the NH Department of Health and Human 
Services (DHHS) and the NYU Health Ev aluation and Analytics Lab (HEAL)  to execute data use 
agreements as we hope to utilize these robust, more efficient emerging resource and/or other 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518394] TIM ELINE  
The planned overall study period is 24 months, including study start up, IF booster, data collection, 
data matching, analysis , and reporting.  
 Table 2: Estimated Project Timeline  
 Study Month  
 1-3 4-5 6 7-12 13-18 19-21 22-24 
Study Preparation         
PRB Approval         
MOP, training development         
Data systems, eCRF development         
Train site research teams         
Regulatory approvals          
Implementation Facilitation         
EMR data abstraction    (Pi[INVESTIGATOR_2268])     
Participant enrollment  and follow -up        
Data matching         
Qualitative interviews and focus groups         
Analysis and Reporting         
Data cleaning and data lock         
Data analy sis        
Final study report and dissemination         
 
IF and support will continue for the sites during study development and start up. We are 
developi[INVESTIGATOR_411014]. Prior to data collectio n, site teams will begin 
pi[INVESTIGATOR_411015]-month of IF will commence to ensure that all 
clinical protocols, resources , and EMR programming is in place. Participant recruitment will begin 
once IF is complete and will take place  over approximately [ADDRESS_518395]   January 15, 20 20 
 
19 
  STUDY POPULATION  
The study population includes 4 sub-samples.  
1. Qualitative : Stakeholders within and outside the hospi[INVESTIGATOR_307], including ED  providers, 
hospi[INVESTIGATOR_187094], ED patients, ED staff, and community opi[INVESTIGATOR_411016].  
2. ED patient process and outcome measures (administrative and health record data) : 
Administrative and health record data for all adult ED patients will be examined to 
assess rates of screening, assessment, BUP eligibility determination, and other process 
measures . Further review of health records and administrative data matching to assess 
process/outcome measures (e.g., claims to assess linkage to tr eatment or filled 
prescriptions) will be performed in ED patients over  the age of 18 screening positive for 
non-medical opi[INVESTIGATOR_2441] v ia a Waiver of C onsent.  
3. Full Study (Research visits) : ED patients who are candidates to receive ED -initiated BUP 
and who meet additional study participation eligibility criteria (described below) will be 
recruited to participate in two research visits (at baseline and Day 30) and data 
matching.  
4. Limited Study (Data matching only ): ED patients who are candidates to receive ED-
initiated BUP and who meet additional study participation eligibility criteria  (described 
below)  but who are unable or unwilling to participate in the F ull Study will be invited to 
provide authorization for  health services review and data matching with available 
registry, claims or administrative data.  
 Qualitative Population Eligibility Criteria  
 Inclusion Criteria  
1. Be a key stakeholder or opi[INVESTIGATOR_411017] -initiated BUP at the hospi[INVESTIGATOR_411018] y, including but not limited to ED staff, ED patients, hospi[INVESTIGATOR_411019].  
2. [ADDRESS_518396] pending legal action or that could prevent participation in the study .  
We estimate that approximately 24 stakeholders (approximately 8 at each site) will participate in interviews or focus groups  at study close .  
 Full Study Population Eligibility Criteria  
 Inclusion Criteria  
1. 18 years of age or older  
2. Be able to speak English sufficiently to understand study procedures  
3. Be a potential candidate for ED -initiated BUP by [CONTACT_411070]: 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518397]   January 15, 20 20 
 
20 a. Clinical determination: Clinical documentation indicating the patient  is a willing 
and eligible candidate for ED -initiated BUP or for whom this can be reasonably 
inferred, including any patient who receives ED-initiated BUP (via direct 
administration, prescription, or direct referral/transfer to BUP provider within 24 
hours  of ED discharge ). 
b. Research determination: Both a and  b below must be true at the time of study 
enrollment:  
a) Assessment conducted by [CONTACT_411071] - (all must be 
true):  
i. has had nonmedical opi[INVESTIGATOR_351065] 7 days,  
ii. meets DSM -5 criteria for moderate or severe OUD,  
iii. denies methadone use within 72 hours of ED visit registration,  
iv. is not engaged in formal MOUD treatment,  
v. is not prescribed opi[INVESTIGATOR_411020],  
vi. reports being interested or “not sure” if interested in receiving BUP 
as elicited on the ED Health Survey during the index ED visit.  
b) Absence of clinical documentation associated with the ED visit indicating 
that the patient is not a candidate for ED- initiated BUP.  
 Exclusion Criteria  
1. Unwilling or unable to provide written informed consent /HIPPA Authorization  for 
research procedures and/or consent for the release of health records and data matching 
for a period of [ADDRESS_518398] pending legal action or that could prevent participation in the study.  
4. Previous participation as a patient -participant in CTN -0079 or previous participation as a 
Full Study participant in the current study ( Note: prior participation in Limited Study or 
qualitative inquiry does not preclude a patient from enrolling  as Full Study participant .) 
5. Present s from a medical -based extended care facility (e.g., skilled nursing facility)  
6. Current research participant in a substance use intervention study.  
7. Inadequate locator information (unable or unwilling to provide two  unique means of 
contact).  
8. Unable or unwilling to complete research visits at baseline and Day 30.  
We anticipate that approximately 120 F ull Study participants (approximately 40 per site) will be 
enrolled to complete research assessments and data matching within the 12- month recruitment 
timeline. We anticipate that as many as an additional 200 ED -BUP candidates will enroll in the 
Limited Study for a total N=[ADDRESS_518399]   January 15, 20 20 
 
21 
 Limited Study Population Eligibility Criteria 
 Inclusion Criteria  
Inclusion criteria is the same as inclusion criteria above,  for the F ull Study. See section 7.2. 
 Exclusion Criteria:  
1. Unwilling or unable to provide written agreement/HIPPA A uthorization to participate  
and/or consent for the release of health  recor ds and data matching for a period of [ADDRESS_518400] pending legal action or that could prevent participation in the study . 
4. Previous participation in the current study  as a L imited Study or Full Study participant  
(Note: prior participation in qualitative inquiry  does not preclude a patient from enrolling) . 
5. Present s from a medical -based extended care facility (e.g., skilled nursing facility).  
 Study Sites  
The study is planned to be conducted in the three Emergency Departments that participated in 
the parent protocol:  
1. Valley Regional Healthcare, Claremont, NH 
2. Catholic Medica l Center, Manchester, NH  
3. Bellevue Hospi[INVESTIGATOR_54246], [LOCATION_001], NY  
For each site, clinical procedures including screening, BUP treatment initiation, and referral to 
ongoing care were approved and implemented between September - October of [ADDRESS_518401] of the ED- initiated BUP clinical program and implementation facilitation strategy and 
identify factors influencing di ffusion and effectiveness. Converging provider and patient 
perspectives and field notes with process measures and intervention outcomes, including 
proportions screened, treated, and engaged in treatment, will provide explanation to 
contextualize and better  understand feasibility, acceptability, and factors associated with the 
rate with which the ED -initiated BUP innovation is adopted and how well it is sustained. Using 
directed content analysis, the qualitative interviews in conjunction with the qualitative  inquiry 
conducted through CTN -0069/[ADDRESS_518402] two primary outcomes to assess (1) clinical program  implementation r each and (2) 
program effectiveness.  
 Program Implementation (Evaluation of Clinical Program 
Reach ) 
The primary implementation outcome is the proportion of patients receiving (i) ED -
initiated/expedited BUP (primary analysis) and (ii) ED-initiated  BUP  (secondary analysis)  
amongst patients who are candidates to receive ED -initiated BUP. 
Rationale: Our primary outcome is a measure of the success of a clinical protocol for identifying 
nonmedical opi[INVESTIGATOR_411021] (i.e., ED -initiated BUP) or indirectly through transfer o f care via “warm” referral to be 
seen within 24 hours for BUP treatment  (i.e., ED -expedited BUP) . We will conduct separate 
analyses for the composite measure of ED -initiated/expedited BUP and ED -initiated BUP  
(rationale discussed below) . The efficacy of BU P is well- established across several domains 
including drug use, overdose, societal costs, quality -of-life and adherence to other ongoing 
treatments, e.g., for HIV. The ED is a meaningful setting in which to initiate treatment. The 
prevailing culture of the ED is that SUD is a non -emergent, chronic condition better addressed 
outside the ED where time and resources are less limited. Rarely do any components of Screening, Brief Intervention (whether brief advice, brief intervention,  or initiation of treatment ), or 
Referral for Treatment occur. Screening itself is not included in the clinical protocol elements of 
the largest emergency medicine organization, the American College of Emergency Physicians 
(ACEP), which are followed by [CONTACT_46431] [ADDRESS_518403] chosen 
to quantify rates of BUP initiation in the ED for the primary outcome and to evaluate downstream 
patient -level outcomes secondarily.  
Description of the Measure and Methods : 
• Receipt of ED -initiated /expedited BUP and Receipt of ED -initiated BUP (numerator)  will 
be operationally defined to include: (1) administration of BUP in the ED, (2) prescription 
for BUP as part of the ED visit, or (3) provision of a specific “warm” referral or transfer of 
care to a provider, clinic, or tr eatment setting with the capacity to administer or prescribe 
BUP within no more than [ADDRESS_518404]   January 15, 20 20 
 
23 • Rationale: A dding ED -expedited BUP  reflects contextual differences impacting the mode 
of treatment delivery identified through CTN -0079 (and, through informal comparison to 
CTN- 0069 implementation trends).  In large academic settings, the model appears to 
center on providers becoming BUP prescribers (i.e., obtaining DATA 2000 X -waiver).  In 
some community ED settings (including sites outside of CTN -0079), however, 
particularly those with locum tenens staffing models, this model is less acceptable and 
less feasible.  Instead, the emphasis often shifts from getting providers X -waivered to 
setting up streamlined, low barrier referral networks with urgent appointment availability. 
The addition of warm handoff for BUP treatment within 24 hours represents a patient -
centered and context -centered good outcome for patients who are not yet in opi[INVESTIGATOR_48530] —as most ED providers do not have DATA 2000 X -waivers to prescribe 
BUP—and it is generally not acceptable (from the hospi[INVESTIGATOR_307], provider, and potentially the 
individual patient perspectives) to prolong  patients’ ED visit for the hours that may be 
necessary for an adequate state of opi[INVESTIGATOR_411022].  As such, measures of quality that do not include ED -expedited BUP 
would not only miss this positive outcome but also potentially  result in reduced 
performance and penalization related to contextual factors that may be outside of the 
control of the ED. The separate analysis of ED -initiated BUP (without ED -expedited 
BUP) is important to support harmonization of  data to permit comparisons across studies 
in which this outcome is used, including CTN -0079. Also,  ED-initiated BUP and ED -
expedited BUP may not have equivalent effects on outcomes. Further study is needed to assess the potential differential impact the m odes of treatment delivery have on 
outcomes.  
• Operationally , ED-expedited BUP  is a warm hand- off to a provider who can provide 
(dispense and/or/prescribe) BUP within [ADDRESS_518405] be  confirmation of this handoff, inclusive of clinical documentation 
in the EMR of medical decision making indicating that the patient is being handed 
off/referred for BUP treatment to a specific provider, clinic, or service with the capacity 
and availability to provide BUP within 24 hours of the patients’ ED discharge.  This could 
include a patient being given an appointment at a specific time and location, transfer to a provider, facility, or inpatient service directly from the ED, or through a pre- arranged 
follow -up mechanism in which a treating provider/facility has agreed to accept patients 
referred from the ED.  Such agreements often exist to ensure access to urgent follow up 
care after ED discharge (for other medical problems and, more recently, OUD) as i t may 
not be practical or possible to schedule appointments, particularly outside of traditional business hours . Neither confirmation of a completed appointment (i.e., patient shows up 
and is seen) nor receipt of BUP at the dedicated follow -up appointment will be required 
as privacy regulations may preclude our obtaining these data and as the patient and treating provider may elect to treat with  alternative regimes  (e.g., methadone, 
naltrexone).  
• Candidate for ED -initiated BUP  (denominator) : In the parent study, the denominator 
included patients with clinical documentation of non- medical opi[INVESTIGATOR_411023]: (a) affirming eligibility and willingness to receive ED -initiated BUP (or for 
whom this could be reasonably be inferred) or (b) confirming recei pt of BUP 
administered or prescribed as part of the ED visit.  For the ancillary study, we will include 
all patients identified to have non- medical opi[INVESTIGATOR_411024] -initiated BUP (or for whom this could be reasonably be inferred). Rationale: 
The rationale for this change is that it should provide more complete capture (expect higher sensitivity and lower specificity) and hold the sites more accountable for ensuring 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518406], inadequate documentation would be more likely to 
dilute positive outcomes  rather than strengthen them. This outcome is somewhat 
analogous to a metric used as a Centers for Medicare and Medicaid Services (CMS) 
accountability measure of quality for t reatment of pneumonia in EDs – the proportion of 
patients who receive antibiotic treatment for pneumonia within 4 hours of ED triage.  The 
denominator includes all patients with diagnosis of pneumonia and excludes only patients for whom specific documentation exists indicating why antibiotics were not 
administered within 4 hours (e.g. , patient refused, atypi[INVESTIGATOR_411025], etc.).  
• Patients may be identified as candidates for ED -initiated BUP through EMR abstraction 
and/or through RA assessments embedded in health surveys using methods adapted 
from CTN -0069.  This represents a change from the parent study, which was limited to 
EMR abstraction. RAs will approach patients in the ED to conduct health surveys 
embedded with questions to screen for non- medical opi[INVESTIGATOR_45705], if positive, assess 
for the main criteria for establishing one’ s eligibility and willingness to receive ED -
initiated BUP (i.e., untreated, moderate to severe OUD; opi[INVESTIGATOR_40483] 7 days; absence of common contraindications; interest in BU P treatment  – as per section 7.2). 
Specific criteria of how to reconcile discrepant EMR and RA obtained data will be 
outlined in the MOP.  Rationale: This additional means of identifying patients who are 
potentially eligible for ED -initiated BUP (and subsequent enrollment) will allow us to 
identify the target population in the event of diminished fidelity to clinical screening for 
non-medical opi[INVESTIGATOR_2441].  Further, we will use these data for quality assurance of clinical 
screening and secondary clinical assess ments.  
 Program Effectiveness  
Amongst participants who received ED- initiated/expedited BUP enrolled in 0079- A1: 
1. with confirmed linkage to formal addiction treatment for OUD within one week following 
ED discharge (operationalized as within 7 -10 days)  
2. who are confirmed to be engaged in formal addiction treatment for OUD on the 30th day 
following ED discharge  
Engagement in treatment on day 30 will be analyzed primarily; linkage will be evaluated secondarily.  
Rationale: Initial treatment linkage and engagement at Day 30 are our primary program 
effectiveness outcomes.  We include linkage to treatment, in part, because  factors outside of the 
ED visit may be attribute d to the 30- day engagement outcome.  However, as the primary outcome 
measure  of the original D’Onofrio  study and CTN -0069, and the most important secondary 
outcome of CTN -0079 and its use in other planned studies, 30 -day engagement appears to be 
emerging as a preferred effectiveness measure. We are also evaluating initial linkage to 
treatment.  We feel these are both important and a good compromise when considering that others 
argue for long- term outcomes ( e.g., 12 month).  Further support of this quality measure is that 
engagement in treatment is associated with other long- term patient outcomes of interest related 
to morbidity and mortality. Also, 30- day outcomes are a common metric in ED research and 
clinical quality measurement (e.g., 30 -day hospi[INVESTIGATOR_5394], mortality).  
Collecting these data across the parent and ancillary studies will likely increase the precision of our estimate and contribute to the limited data we currently have on this outcome, which includes 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518407]   January 15, 20 20 
 
25 the 78% rate observed in the original D’Onofrio  efficacy trial and a notably lower rate observed in 
real-world clinical practice. According to unpublished raw data from Andrew Herring, MD, linkage 
to treatment has been observed in approximately 30- 40% of patients in [LOCATION_004]’s ED- BRIDGE 
program. This discrepancy in treatment engagement after ED discharge strongly supports our 
further investigation of effectiveness outcomes without the heavily supported conditions present 
in efficacy trials. 
Measure description: The treatment linkage/engagement measure must be confirmed by [CONTACT_411072]/or treating clinician or other objective means (e.g., medical record review). Linkage to  treatment for OUD will be defined as attendance at formal addiction treatment 
following the ED visit.  Engagement in treatm ent for OUD will be defined as enrollment in formal 
addiction treatment on the 30
th day following  ED discharge . Formal addiction treatment will be 
those treatments consistent with the American Society of Addiction Medicine’s (ASAM) level of 
care (1- 4) and will include a range of clinical settings, including office -based providers of BUP or 
naltrexone, OTPs, intensive outpatient, inpatient, or residential treatments.  
 Secondary Outcomes  
Secondary Implementation outcomes will include other measures of reach, including evaluating 
ED-initiated BUP as a function of time. Other RE -AIM model dimensions to be assessed include 
Adoption (the proportion of providers who deliver ED -initiated /expedited BUP) and 
Implementation fidelity (proportions for adherence to clinical actions associated with the delivery 
of ED -initiated BUP). Maintenance will be assessed by [CONTACT_411073] - and setting- level 
outcomes ≥ 6 months after the cessation of all study -supported IF (i.e., the Maintenance Period).  
As in the parent study, a range of secondary effectiveness measures will be assessed at the index 
ED and Day 30 visits  for Full Study participants only, including but not limited to:  
• Self-reported days of opi[INVESTIGATOR_74480] (TLFB)  
• UDS results at [ADDRESS_518408] index ED visit  
• Overdose events  
• Healthcare utilization  
• Quality of Life, Health, and Treatment Effectiveness ( PROMIS -29, PHQ -9, TEA)  
• Treatment satisfaction and acceptability  
Process measures related to the clinical protocol include but are not limited to:  
• Proportion of ED patients triaged who are screened for non -medical opi[INVESTIGATOR_2441]  
• Proportion of patients screened who are positive for non -medical opi[INVESTIGATOR_2441] 
• Among those positive:  
- Proportion of patients  who are candidates to receive ED -initiated BUP  
- Proportion of patients  who receive ED -initiated BUP  (and the means of delivery,  
i.e., direct administration, prescription, or indirectly via warm referral within 24 
hours)   
- Number meeting inclusion/exclusion criteria for ED -initiated BUP  
• DSM -5 moderate- to-severe OUD  
• Use opi[INVESTIGATOR_411026] [ADDRESS_518409]   January 15, 20 20 
 
26 • Not engaged in medication treatment for OUD  
• Proportion who received facilitated referral for treatment amongst those who received 
some form of ED -initiated BUP. 
• Fidelity  
- Critical actions completed 
Implementation barriers and facilitators, include:  
• Stakeholder acceptability over time (key informant interviews, focus groups)  
• ED staff, patient, provider, community barriers and facilitators (key informant interviews, 
focus groups)  
 Tertiary and Exploratory Outcomes  
In addition to our revised primary means of assessing the programmatic implementation outcome, 
we will track methods of data capture to allow us to assess several permutations of this outcome 
(Reach) to: (i) better match the parent study outcome for improved comparison over time across 
the parent and ancillary studies and (ii) to refine quality measures that provide more reliable, valid, 
and complete outcome data and that adequately capture the most salient outcomes in a way that 
is practical for research and clinical performance monitoring.  For example, other measures of 
reach will include permutations of how the numerator or denominator are defined (e.g. , excluding 
referrals; including only patients identified through EMR documentation).  Permutations to  
effectiveness outcomes and analyses will include evaluation of linkage and engagement ov er 
different timeframes (e.g., linkage within 72 hours, 14 days, and 30 days; time- to-event analyses), 
and evaluations including alternative denominators (e.g., including participants who did not 
receive ED -initiated BUP). Arguments for shorter timelines are for cases in which BUP is not 
prescribed; arguments for longer timelines include more remote settings with less treatment availability or if extended -release BUP formulations were used.  
Because ED -initiated treatment for OUD is in its infancy, it is ess ential to first evaluate 
performance using an approach that maximizes validity and reliability and provides more 
granular level detail to measure and monitor quality at specific points in the process. Further, it permits analyses of how patient -level characteristics influence completion of measures and 
effectiveness, which is important to ensuring equitable care. The data collected through the clinical trial using labor- intensive methods will provide a resource – gold standard measures  
– against which we can compare agreement with quality measures using registry, claims, or 
other data that will become more feasible as the data infrastructure improves. Although we are unaware of any National Quality Forum (NQF) -endorsed measures specific to the 
initiation of pharmacotherapy for OUD in the ED and linkage to ongoing treatment, there are 
measures with potential adaptability to be useable for quality measurement (e.g., NQF 
#2605, which evaluates the percent linked to alcohol/drug services after an alcohol/drug-
related ED visit at 7 days and 30 days). We will assess the utility of using administrative 
databases (pending availability) for pragmatic evaluation of secondary patient -level 
outcomes and costs over time such as data from EMRs, health services claims, ambul ance 
reports (transports to EDs, overdose events, costs), the PDMP, and the Departments of 
Health (vital statistics, mortality), Criminal Justice, and Homeless Services. [CONTACT_376600] and team members’ participation in CTN -[ADDRESS_518410]   January 15, 20 20 
 
27 
 STUDY PROCEDURES  
Study procedures are divided into (1) Implementation Facilitation; (2) clinical protocol 
sustainability ; (3) qualitative procedures and (4) research participant  procedures . 
 Implementation Facilitation (I F) 
An IF booster will be delivered to study sites at the end of the IF Period prior to study start ( data 
collection ) using the developed IF procedures detailed in CTN -0069/ -0079. The purpose of this 
“IF booster” is to provide final feedback and help sites transition to independence (designate 
personnel, etc.) and ensure that processes are in place to allow research sta ff to collect the 
needed data with minimal influence on clinical activities.   
Key goals of IF during this time period are:  
1. Fine tune clinical protocols and provide practical advice. 
2. Provide final academic detailing to ensure adequate knowledge, skills, and  ability to 
continue t he clinical program without study support . 
3. Ensure sites are linked to adequate local and national resources for clinical support . 
4. Support an internal continuous quality improvement  (CQI) and feedback 
system/performance monitoring. 
We will work with local champi[INVESTIGATOR_411027]- out assessments (surveys, focus groups, and qualitative interviews) to 
further refine site- specific clinical protocols and implementation -sustainability plans. We will 
confirm clinical documentation procedures are established to ensure pragmatic data collection and abstraction for clinical performance moni toring and research assessments.  
No further study intervention will occur once trial data collection has begun (i.e., during the Post -
IF and Maintenance Periods) with the caveat that the ED -initiated BUP clinical program(s) have 
not failed to be maintained as discussed ( see section 5.4). 
 Elements of Implementation Facilitation  
IF will be based on a manualized program developed by [CONTACT_411074]  [13] that has 
had significant impact on implementing healthcare practices in clinical settings. Building on the 
mixed -methods analysis conducted during the formative evaluation, we will use the Promoting 
Action on Research Implementation in Health Services  (PARiHS ) framework to tailor the IF for 
site-specific needs. The facilitators and barriers identified by [CONTACT_411075], providers, community 
stakeholders, and patients and will be characterized according to the PARiHS sub- elements of 
patient and clinical experience (communication, knowledgeable and empathetic providers), receptive context (resources to provide addiction treatments), and culture (value of team -based 
approach) identified. The individual components of IF are described below.  
[IP_ADDRESS]  External Facilitator  
Study Investigator content experts  will work with local champi[INVESTIGATOR_411028]-specific needs and 
applied as needed over the course of the study . They will coach and mentor local champi[INVESTIGATOR_411029].  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518411]   January 15, 20 20 
 
28 [IP_ADDRESS]  Local Champi[INVESTIGATOR_411030] -initiated BUP clinical 
program. Local champi[INVESTIGATOR_411031]-person orientation and trainings as well as 
conference calls with external facilitators during which challenges, barriers, facilitators and 
strategies  will be discussed and documented.  
[IP_ADDRESS]  Academic Detailing 
Academic detailing involves trained clinician consultants visiting other clinicians to share unbiased 
information about patient assessment and treatment with the goal of improving quality of care 
[13]. All ED and community providers who may be involved in the initiation or continuation of BUP 
or assisting with the referral process will be o ffered educational sessions on OUD and BUP 
training, specifically tailored to each provider’s tasks . Data from the f ormative and ongoing 
evaluation during CTN [ZIP_CODE] will be used to potentially modify, remove or add strategies to 
enhance implementation. We will address practical issues such as efficient use of the EMR  for 
prompts, provide tools and web- based resources such as pcssmat.org and the NIDA  and Yale  
websites on initiating buprenorphine in the ED. Training strategies will be based on adult learning 
theory and include interactive didactic presentations on the effectiveness and safety of prescribing 
BUP and s kills-based practice sessions, including techniques to enhance motivation. We will offer 
opportunities and facilitate completing the DATA 2000 waiver for BUP prescribing (currently, free of charge in [LOCATION_001] and New Hampshire).  
 Advising on ED-Initiated B UP Clinical (Non -Research) 
Sustainability  
Serving in an advisory and consultant capacity, we will work with the clinical sites to help them 
refine  previously developed clinical protocol s for ED -initiated BUP with facilitated referral. While 
informed and supported by [CONTACT_79161], these are clinical guidelines , the contents of which and 
adherence to, will not be governed by [CONTACT_31295]. The induction and stabilization guidelines  
contain a checklist of critical actions similar to those  previously tested by D’Onofrio et al .[3] We 
will provide ongoing consultation to help monitor, support, and refine implementation during the 
IF activities/ booster  prior to the start of  data collection and enrollment . Adherence to the clinical 
protocol and, specifically the critical actions related to BUP induction, will be measured by [CONTACT_411076] (see section 9.2.2 ). 
 Performance Monitoring and Feedback  
We will work with ED leaders  and other members of the ED staff to incorporate clinician 
performance related to BUP -initiation and facilitated referral into the department’s standard 
continuous quality improvement  (CQI) and feedback  practices. Once local CQI methods are 
established, sites will share CQI  data with investigators  as available.  
 Learning Colla borative 
Building upon the success of the previous learning collaborative calls for CTN -0079, a Learning 
Collaborative will be formed during the IF booster month with sites’ local champi[INVESTIGATOR_5458], and other 
key stakeholders, to participate in conference calls and or in- person meetings  to promote shared 
learning regarding issues promoting and hindering implementation of addiction treatment. It will provide a dedicated time to discuss site -specific updates, case studies and clinical management, 
challenges and possible solutions for implementation of  ED-initiated buprenorphine with referral 
to treatment services . Detailed notes will be maintained; this information will be integrated  into 
the evaluation and used to identify site needs that could benefit from targeted IF during this month.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518412] and support both overall study goals. This dataset will provide the study primary implementation outcome, (i.e., the proportion of 
patients who receive ED -initiated BUP amongst patients who have been determined to be 
candidates for  ED-initiated BUP ). 
 Clinical Protocol Adherence Log  
The Clinical Protocol Adherence L og provides  documentation of critical actions  (and non -critical 
actions of interest) for ED -initiated BUP including, but no t limited to : 
• Meeting criteria for DSM -5 moderate -to-severe OUD  confirmed  
• Opi[INVESTIGATOR_40483] 7 days confirmed (by [CONTACT_411077]) 
• Assessment of opi[INVESTIGATOR_411032] (e.g., Clinical Opi[INVESTIGATOR_9721] 
(COWS ) score)  
• hcG obtained  
• ED-initiated /expedited BUP provided  
• BUP education and induction instructions provided 
• Referral for treatment for OUD  provided 
Patients will be identified as unique or repeat patients. Basic demographic information (race, 
ethnicity, sex,  age, insurance,  etc.) will also be collected. Da ta are acquired at the patient level  
for this form  to allow for QA of abstraction. All data will be de- identified when entered in Advantage 
eClinical.  
 Qualitative Procedures  
At each of the study sites, we will conduct focus groups and/or individual qualitative interviews 
with a purposive sample of key stakeholders near the close of the study. Purposive sampling is a 
well-established method in qualitative studies and is designed to identify study participants who 
have direct experience with or knowledge of the phenomenon of interest, in this case OUDs and ED-initiation of BUP with referral for treatment . We have chosen to use focus groups given their 
suitability for generating data from multiple perspectives regarding the organizational and 
individual level factors impacting complex processes when available, and will use one- on-one 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518413] inclusion 
of perspectives when it is neither feasible nor practical to arrange a suitable focus group  [14].  
 Focus Groups and Qualitative Interviews  
We w ill enroll multiple stakeholders, including but not limited to: ED patients, nurses, social 
workers, physicians, NPs, PAs, pharmacists, physician and nursing directors  at each ED site. In 
addition, key stakeholders with knowledge or insight into the community -wide impact relating to 
CTN- 0079 will be invited to participate in focus groups and qualitative interviews near study close. 
A subset of key stakeholders at each site may also be invited to participate in a focus group and/or 
interview to collect interim information if sustainability  fails at the site, as defined in section 5.5. 
For staff, we will primarily use focus groups given their suitability for generating data from multiple 
perspectives regarding the organizational and individual level factors impacting complex 
processes whereby [CONTACT_411078]  [14]. Focus 
groups will be conducted with approximately  4-8 study participants  each  [15]. 
 Development of Focus Group and Interview Guides  
The focus group guides will be informed by [CONTACT_411079] “grand tour” 
questions designed to establish rapport and elicit open- ended responses. Probes will be used to 
understand specific details of those experiences and allow for clarification of ideas.  
 Conduct of Focus Groups/Interviews  
Focus groups and qualitative interviews will be conducted by [INVESTIGATOR_124]. Kathryn Hawk and/or other  
adequately trained study personnel . All interviews will be audio recorded with the knowledge and 
permission of the participants.  
 Informed Consent Procedures  
Potential participants recruited for interviews and focus groups will meet with research staff to review all significant elements of the study via an IRB approved verbal script, and the potential 
participant will be given an opportunity to ask any questions. Following this discussion, and prior 
to collection of any study -related information, verbal consent to participate in the study will be 
obtained by [CONTACT_3647]. Taking part in the focus group and/or interview is the individual’s 
agreement to participate, including for audiotapi[INVESTIGATOR_007].  
We will work with the EDs and community treatment programs to provide staff assurances that 
their participation in the research will in no way affect their employment status either positively or 
negatively.  Participants participating in focus groups and qualitative interviews will be reminded that 
these sessions will involve discussion of sensitive topi[INVESTIGATOR_1102], including information regarding health 
status, opi[INVESTIGATOR_411033]. Focus groups and interviews will be voluntary and 
information collected for research purposes will not become part of staff’s personnel records or patients’ medical records.  
There is no written (signed) authorization form for focus group participants ; a Waiver of 
Documentation of Consent  will be  secured, as was done in the parent study . 
Individuals who refuse to participate or who withdraw from the study will be treated without 
prejudice.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518414] will be maintained until the transcripts are reviewed in their entirety and 
no questions related to inaudible or inaccurately transcribed portions remain. These recordings 
will subsequently be destroyed. 
 Qualitative Participant  Incentives  
Patient s and providers will receive a $25 incentive for participating in a focus group or a one -on-
one qualitative interview. See section 12.13 for Qualitative Statistical Analyses . 
 Research Participant Procedures  
 Full Study Participants  
Patients who are determined to meet Full Study eligib ility criteria  (section 7.2) will be invited to 
participate in the Full Study, which consists of two research visits and providing authorization for 
research staff to access their health records and to link/ match  their Protected Health Information 
(PHI) an d Personally Identif iable  Information (PII) to administrative data (e.g., PDMP, claims ) for 
a period beginning 1 year prior to study enrollment through  2 years following study enrollment . As 
described in the Manual of Operations  (MOP ), the baseline research visit will ideally occur at the 
index ED visit or within [ADDRESS_518415] discharge. The Day 30 follow -up visit ([ADDRESS_518416] ED discharge) will ideally occur 
no more than [ADDRESS_518417] this point.  
[IP_ADDRESS]  Recruitment  
Research staff will work rotating shifts in the ED, providing coverage on weekdays, evenings , and 
weekends.  Shifts will be s cheduled so that patient s can be recruited on all days of the week.  
During recruitment shifts, research staff will approach ED patients  in a prioritized  order, such that 
patients who are most likely to be eligible will be approached  first. For example, pat ients who 
present to the ED seeking treatment for OUD or who were identified through triage screening to 
have non- medical opi[INVESTIGATOR_411034]; prioritization procedures 
will be further described in the MOP.  The integration of opi[INVESTIGATOR_411035] -
0079 will facilitate pragmatic identification of potential participants.  
Research staff will screen and assess ED patients for study eligibility using questions embedded 
in a health survey  (ED Health Survey) . We have successfully used the strategy of embedding 
substance use questions in a general health survey as a method to screen for drug and alcohol use.[16, 17]  Embedded questions have also been noted by [CONTACT_411080] -reported behavior.   
NIDA CTN-0079-A1  Version 2.[ADDRESS_518418]   January 15, 20 20 
 
32 Upon approach, the RA will use an IRB -approved script to seek permission  to complete the ED 
Health S urvey . A Waiver of Documentation of Informed Consent will be requested to complete 
the ED Health Survey.  The ED Health Survey will begin with introductory questions (e.g., patients’ 
access to a primary care provider and transportation) followed by  [CONTACT_411081] 
(tobacco, alcohol) prior to asking about opi[INVESTIGATOR_2441]. Patients endorsing non-medical opi[INVESTIGATOR_411036] a series of simple questions  to assess 
whether they are likely candidates for ED -initiated BUP , including the DSM -[ADDRESS_518419] for OUD 
(see section 7.2) and,  if so, additional questions to determine eligibility  for study participation (e.g., 
prisoner status  assessment ). 
Patients who receive ED-initiated BUP  during times without  research staff coverage will be 
contact[CONTACT_411082].  Candidates 
who do not receive BUP will not be contact[CONTACT_411083][INVESTIGATOR_347432]. As in the 
parent study, r esearch staff w ill utilize available contact [CONTACT_3031], including information 
provided at registration or documented in the EMR, to contact [CONTACT_397456], assess eligibility, and offer study participation. Each site’s clinical protocol includes a procedure to notify E D pa tients 
that clinical or res earch staff may contact [CONTACT_411084]/or to discuss 
participation in a research study . Patients may opt out of contact [CONTACT_411085]. Assessment 
of study eligibility will be conducted by [CONTACT_411086] s taff and may be completed by [CONTACT_411087] (upon return). Candidates who are determined to be eligible for and interested in study participation will be scheduled for written consent and baseline assessments to be completed in person, ideally within [ADDRESS_518420] information, 
homelessness, admission to a treatment program, or other reasons. Of the patients reached, it is expected that some may choose not to participate and that some patients may fail to present for 
the baseline visit within the visit window. Research staff will make repeated attempts (at varying 
times of the day - morning, afternoon, evening) to contact [CONTACT_411088] (i.e., call, text, email). Research staff will also strive to reduce barriers to participation by [CONTACT_411089] a time and location that is convenient for the 
participant. All candidates will be informed that they will receive compensation for participation.  
We will strive to keep recruitment relatively even across all sites  through purposive sampling and 
employing a recruitment strategy, defined in the MOP, that includes enrollment rate limits based 
on the relative number of participants  enrolled at each site.  As our effectiveness outcomes focus 
primarily on recipi[INVESTIGATOR_411037] -initiated BUP, we will also employ a recruitment strategy that 
preferentially enrolls patients  receiving ED- initiated BUP to those  not receiving ED -initiated BUP . 
Similarly, we will preferentially enroll females as they are known to be  underrepresented.  
[IP_ADDRESS]  I nformed Consent  
Patients endorsing non -medical opi[INVESTIGATOR_411038], will be asked to provide verbal consent to complete screening procedures.  After the individual  has provided verbal (not signed) consent, research 
staff will complete the DSM -[ADDRESS_518421] for OUD , demographic information, and confirm that the 
candidate meets all the inclusion criteria and none of the exclusion criteria.  Candidates who meet 
all eligibility criteria will be offered participation . Reasons for exclusion or non- participation will be 
documented. Candidates who do not meet eligibility for the Full Study, will be assessed for 
participation in the L imited Study ( section 10.15). 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518422] to use  of a compound authorization form that serves 
as a combined consent and HIPAA disclosure form allowing study access to PHI and PII in the 
participant’s health record. 
Candidates will be informed that their medical care will not be adversely affected if they decline 
to participate in this study. The candidate will be informed that their participation is voluntary, and 
they may withdraw from the study at any time, for any reason, and without penalty. Individuals 
who refuse to participate or who withdraw from the study will be treated without prejudice. 
Future research: We will seek permission to contact [CONTACT_411090] ; however , permission for future contact [CONTACT_411091].  
The candidate will consent by [CONTACT_200874]. The person obtaining 
consent will also sign and date the consent document. The participant should be given a copy of 
the signed consent to keep for their records. Study sites will be responsible for maintaining original signed consent forms as source documents for quality assurance review and regulatory compliance.  
[IP_ADDRESS]  Eligibility Confirmation and Enrollment  
Once eligibility is confirmed, and all consents are fully executed, the candidate will be considered 
enrolled in the study. The enrollment procedures will be captured through a centralized process 
managed by [CONTACT_200824] (DSC).  Patients who do not complete screening 
or who are otherwise found to be ineligible for participation in the F ull Study will be considered 
screen failures.  These individuals who fail screening or refuse F ull Study participation, may be 
assessed for Limited Study participation (section 10.15).  
[IP_ADDRESS]  Baseline Procedures  
Baseline procedures will continue with structured assessments on quality of life, substance  use, 
and healthcare utilization. See Table [ADDRESS_518423] of study assessments. Baseline 
procedures will ideally be completed at or within 72 hours of ED discharge by [CONTACT_411092].  
[IP_ADDRESS]  Intervention  
All patients who screen positive for non -medical opi[INVESTIGATOR_411039]. 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518424]   January 15, 20 20 
 
34 [IP_ADDRESS]  Follow -up Visit (Day 30)  
The follow -up research visit will assess engagement in treatment on the 30th day after discharge 
from the index ED visit. At the follow -up visit, participants will be asked to provide a urine sample 
and complete specified research assessments ( see Table 3: Schedule of Assessment s). 
[IP_ADDRESS]  Participant Retention  
Rigorous retention strategies will be employed to maintain contact [CONTACT_411093]. Broadly, retention methods may include 
outreach to the participant and their identified contacts through mailed letters, email reminders, 
phone calls, text messaging, social media, in- person contact, and/or public database searches. 
All tracking and retention materials will be IRB -approved.  
[IP_ADDRESS]  Premature Participant Withdrawal 
All participants will be followed for the duration of the study unless they withdraw consent, die, or 
the investigator or sponsor decides to discontinue their enrollment for any reason. Reasons for 
the investigator or sponsor terminating a participant from the study may include, but are not limited 
to, clinical documentation post enrollment that the patient is not a candidate for ED -initiated BUP, 
the participant becoming a threat to self or others, lack of funding, or DSMB early termination of 
the study for safety or effectiveness reasons.  
[IP_ADDRESS]  Participant Reimbursement  
Participants will be compensated for their parti cipation in the Full Study. Each  will receive $75 for 
completion of screening and baseline assessments and $100 for the Day 30 follow -up visit.  
 L imited Stud y Participants  
ED patients who do not meet Full Study eligibility criteria  or who refuse F ull Study participation  
may be eligible to participate in the Limited Study. Limited S tudy participants will be identified 
through the same recruitment process as Full Study participants ; however, once candidates 
screen out for the Full Study (see sections 7 .2 and 7 .3), they will continue to be assessed for 
possible Limited Study participat ion. Limited Study participation will only be offered to those 
candidates who complete screening in person  (i.e., patients who are no longer in the hospi[INVESTIGATOR_411040] F ull Study if they are eligible) . Once all inclusion crit eria and 
none of the exclusion criteria have been met, the candidate will be presented with an Information 
Sheet outlining the purpose of the L imited Study, information to be accessed, and how the 
information will be used. If the patient remains interested in participating, the patient will be asked 
to certify they have read and understand the study procedures , as well as , provide consent 
authorizing release of medical information and use of PHI and PII so that we may lin k their survey 
and other research data with administrative databases . The authorization period will be valid for 
two years from the date of signing  (i.e., study enrollment) and one year retrospectively  (candidates 
will have the ability to opt out of releasing retrospective data one year prior to study enrollment) . 
The candidate will be provided sufficient time to read through both the medical release  and 
information sheet  and will receive a verbal explanation of study procedures suited to their 
comprehension level. Candidates will be given time to ask questions before signing the medical 
release and information sheet . Limited Study participants will receive a pamphlet on  OUD and 
receive $[ADDRESS_518425] through a centralized process managed by [CONTACT_411094] (DSC). Once the participant has completed screening and is enrolled 
into the L imited Study, all remaining assessments will be completed via chart review or available 
data and without participant input. See Table 3: Schedule of Research Assessments  – Full and 
Limited Study. The data for these assessments will be abstracted via manual searches from 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518426]   January 15, 20 20 
 
35 EMRs and databases ( e.g., PDMP) according to procedures established in the parent study. We 
will also link Limited Study participants’ PHI and/or PII to administrative data for the purposes of 
data matching, pending availability (Data Use Agreements)  as will be done with the Full S tudy 
population and all adult ED patients screening positive for non- medical opi[INVESTIGATOR_2441], via a Waiver 
of Consent . 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518427]   January 15, 20 20 
 
36 
 RESEARCH ASSESSMENTS  
 Table 3: Schedule of Research Assessments – Full and Limited 
Study  
 All Full Study  Limited 
Study  
Assessment * Screening  & 
Enrollment  Baseline  Day 30  Day 30  
ELIGIBILITY  
Introductory Script/Permission for ED Health Survey  X    
ED Health Survey  X    
Verbal Consent  X    
DSM -5 X    
Additional Demographics  X    
Prisoner Status Assessment  X    
Patient Eligibility  X    
Enrollment (Inclusion/Exclusion)  X    
Written Informed Consent  (i.e., compound 
authorization form)  (Full Study only)  X    
Information Sheet  (with  authorization )(Limited 
Study only)  X    
Medical Releases  X    
GENERAL  
Demographics  X    
Locator Information Form   X X  
Other Substance Use   X   
PROMIS -29  X X  
Motivations, Attitudes and Expectations   X   
Study Completion    X X 
HEALTH SERVICES  
Inpatient Utilization   X X  
Outpatient Utilization   X X  
Health Status   X X  
Healthcare Visit Logistics   X   
ED Visit Review   X  X** 
ED Visits and Hospi[INVESTIGATOR_602]    X X 
PROCESS OUTCOMES  
Engagement in Treatment  - Patient    X  
Engagement in Treatment - Facility    X X 
Prescription Drug Monitoring    X X 
Treatment Satisfaction/Acceptability    X  
Treatment Effectiveness Assessment (TEA)   X X  
OPI[INVESTIGATOR_411041] -Back (TLFB)   X X  
Urine Drug Screen  X X  
Overdose Events & Risk Factors   X X  
SAFETY  
Safety Events   X X X 
Mental Health Assessment+  X X  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518428]   January 15, 20 20 
 
37 * All participant -facing documents will be reviewed/approved by [CONTACT_1201]. Minor edits may be made to assessments 
(e.g., grammar, punctuation, directions, system programming, etc.) as needed. Assessments will only be submitted 
for re -revie w if information to be collected is changed (e.g., addition of new questions.).  
**To be completed after enrollment and prior to Day 30 for Limited Study participants  
+As triggered by [CONTACT_411095].  
 Eligibility  
ED Health Survey : This assessment will be conducted with patient permission through a Waiver 
of Documentation of Informed Consent. It will include questions about illicit opi[INVESTIGATOR_411042] a general health and substance use screener that also includes questions about tobacco and 
alcohol use. This form will be completed via self -report and potentially  supplemented via medical 
record abstraction (e.g., rather than re- asking data collected clinically, the RA may review data 
with the patient to ensure accuracy and minimize patient frustration associated with redundancy) 
for all study candidates.   
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM -5): The DSM -5 
criteria are assessed during screening to determine a current diagnosis  of moderate- to-severe 
opi[INVESTIGATOR_2427]. This assessment will be completed electronically in eClinical and will be automatically scored.  
Additional Demographics: The additional demographics form collects information on health 
insurance, income, employment patterns, and housing information. This form is completed once 
at screening for all study candidates. 
Prisoner Status Assessment: The Prisoner Status Assessment is a brief form collecting 
information related to current detainment, house arrest and/or probation status to determine whether the candidate meets the definition of a prisoner as delineated in 45 CFR 46.303(c) at the 
time of the index ED visit. This form will be completed once at screening for both F ull and L imited 
Study participants. Candidates  meeting prisoner status at screening will not be enrolled in either 
the Full or L imited study.  
Eligibility Measures : These forms collect information regarding study eligibility. The Patient 
Eligibility form documents eligibility criteria collected during screening. Prior to informed consent , 
the inclusion and exclusion criteria are assessed and documented on the Inclusion/Exclusion 
Checklist and Enrollment form. Only individuals who continue to meet study eligibility criteria are allowed to continue with the screening process, and enrollment. Both limited and Full Study 
participants will complete eligibility assessments.  
 General  
Demographics : The demographics form collects information about demographic characteristics 
of the study candidate, including date of birth, sex, racial /ethnic group, educational level, marital 
status,  and employment status.  The demographics form will be completed once at enrollment for 
both Full and Limited Study participants.  
Locator Information Form : A locator form is used to obtain information to assist in finding patient-
participants during follow -up. This form collects the participant’s current address, email addr ess, 
and phone numbers. In order to facilitate locating participants if direct contact [CONTACT_200843], addresses and phone numbers of family/friends who may know how to reach the 
participant are collected, as well as information such as social security number, driver’s license 
number and other information to aid in searches of public records. Two valid contacts are required 
for study eligibility. This information will be collected at baseline and updated at the Day [ADDRESS_518429]   January 15, 20 20 
 
38 up for Full Study participants only. Data entered in this form will be encrypted and will not be used 
in data analyses.  
Other Substance Use: Selected questions from the Alcohol, Smoking and Substance Involvement 
Screening Test (ASSIST) -lite [18] will be used to assess drug and alcohol use over the past 3 
months and will be asked at baseline for F ull Study participants only.  
PROMIS -29: Health -related quality of life (HRQoL) will be measured using the Patient -Reported 
Outcomes Measurement Information System (PROMIS).[19, 20]  PROMIS was developed using 
item response theory, with support from the NIH. Because of its foundation, PROMIS is able to 
improve upon common deficiencies of existing, widely -used, HRQoL instruments capable of 
generating a single health utility index value for the calculation of QALYs  [21-24] including: floor 
and ceiling effects among participants who are especially ill or healthy, respectively, and imprecise questions that blend concepts. [25] The PROMIS -Preference (PROPr) scoring system 
uses the respondent’s scores for each of the following PROMIS domains to calculate a health utility index value that represents the general US population’s preference for the respondent’s current health state: Cognitive Function– Abilities, Depression, Fatigue, Pain Interference, 
Physical Function, Sleep Disturbance, and Ability to Participate in Social Roles and Activities. [26, 
27] PROMIS has 5 levels for each domain: no problems, slight problems, moderate problems, 
severe problems, and extreme problems. The health- utility value produced by [CONTACT_411096] -0.[ADDRESS_518430] validity for PROPr has been 
demonstrated using other HRQoL instruments and two large datasets from the general US 
population. [25] The health- utility value is then used to calculate QALYs, as our team, and many 
others have done in similar studies . 
Motivations, Attitudes and Expectations:  Motivation for participating in the study and attitudes and 
expectations regarding medication treatment for OUD are collected once at baseline for Full Study 
participants.  
Study Completion: This form tracks the participant’s status in the study  through the Day 30 visit . 
It is completed for both F ull and L imited Study participants after completion of the Day 30 follow -
up or once the visit window lapses for participants who do not complete the Day 30 follow -up. 
This form is used in data analyses to address variables such as treatment retention and 
completion. This form also provides a location for the site PI [INVESTIGATOR_411043] . 
 Health Services  
Health Services Utilization Inpatient and Health Services Utilization Outpatient: A brief, structured 
interview regarding health care utilization (inpatient and outpatient) will be used, which collects 
information on the type and amount of services received. This includes ED visits, hospi[INVESTIGATOR_602], primary medical care visits (excluding those for buprenorphine treatment and 12 -step group 
sources of support (e.g., Narcotics Anonymous). It is completed at baseline and at the Day 30 follow -up visit for Full Study participants only.  
Healthcare Visit Logistics: The Healthcare Visit Logistics form collects informa tion on distance to 
healthcare providers (e.g., how many miles patient -participants drive to providers). This form is 
completed once at baseline for Full Study participants.  
Health Status: The Health Status form collects information on HIV and Hepatitis C status, pain 
(PEG), and psychological health (PHQ- 9), usual care and reason for the ED visit. Health status 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518431] had  
“Thoughts that you would be better off dead, or of hurting yourself in some way” over the past two 
weeks in the PHQ -9 section of the form.  
ED Visit Review : The ED Visit Review form collects information about the index ED visit including 
enrollment date, discharge date and time, chief complaint, critical actions completed, and discharge diagnosis. It is completed by [CONTACT_411097] F ull Study participants.  
ED Visits and Hospi[INVESTIGATOR_602] : The ED Visits and Hospi[INVESTIGATOR_411044] -
up. It is completed at the Day 30 follow -up visit. Data are gathered by [CONTACT_411098] F ull Study participants.  
 Process Outcomes  
Engagement in Treatment Survey : At the Day 30 follow -up visit F ull Study participants will be 
asked to report whether they are engaged in formal addiction treatment. Data will be reported on 
the Engagement in Treatment: Patient survey. The outcome will be confirmed with the addic tion 
treatment provider using the Engagement in Treatment: Facility survey, which includes the type of treatment the participant is receiving, i.e., methadone, buprenorphine and/or naltrexone 
treatment, detoxification, inpatient or outpatient treatment. Date of admission is recorded as well 
as the level of treatment received according to ASAM Levels of care, such as Level I: Outpatient Treatment; Level II: Intensive outpatient treatment (including partial hospi[INVESTIGATOR_059]); Level III: 
Clinically managed residential/inpatient treatment; Level IV: Medically managed intensive 
inpatient treatment or Other -specified. Engagement in Treatment: Facility survey will be 
completed with both F ull and Limited Study participants. ED visit is considered Day 0; 
Engagement is  assessed on Day 30.  
Prescription Drug Monitoring: The states’ Prescription Drug Monitoring Programs will be accessed 
to identify all opi[INVESTIGATOR_411045] -up period (date of ED 
discharge through Day 30) . This form w ill be completed once at the Day 30 visit  for both F ull and 
Limited Study participants. This form is completed via database review and without participant 
input.  
Treatment Satisfaction/ Acceptability : This form will be completed at the Day [ADDRESS_518432] information on satisfaction with and acceptability of 
OUD treatment received throughout the study.  
Treatment Effectiveness Assessment: This form will be completed at the baseline and Day 3 0 
follow -up visit  for Full Study participants . This form collects self -report data across four domains:  
substance use, health, lifestyle, and community.  
 Opi[INVESTIGATOR_411046] -Back (TLFB) : The Timeline Follow -Back [28] procedure will be used to elicit the 
Full Study participant’s self -reported use of illicit substances at baseline and throughout study 
participation. The TLFB will be administered at baseline for the 7- day period prior to the index ED 
visit. At the Day [ADDRESS_518433]   January 15, 20 20 
 
40 Overdose Events and Risk Factors : We will ask Full Study participants about opi[INVESTIGATOR_2480]- related 
overdose events, overdose prevention, and overdose risk factors. This form will be completed at 
baseline and at the Day -30 follow -up visit for F ull Study participants only.  
Urine Drug Screen: Urine testing will be performed for the presence of the following drugs: opi[INVESTIGATOR_2438], 
oxycodone, PCP, benzodiazepi[INVESTIGATOR_1651], cocaine, methamphetamine, amphetamine, 3.4-
methylenedioxy -methamphetamine (MDMA), tetrahydrocannabinol (THC), barbiturate, 
methadone, fentanyl, and buprenorphine. The urine drug screen is conducted by [CONTACT_411099]. UDS results will not be entered into the medical chart. The UDS is 
performed at baseline and the Day 30 follow -up visit for Full Study participants. Urine testing 
supplies will b e provided to the sites.  
Overdose Events and Risk Factors: The Overdose Events and Risk Factors form is completed at 
baseline and Day [ADDRESS_518434] 30 -day opi[INVESTIGATOR_411047].  
 Safety  
Mental Health Assessment : The Health Status  form contains a q uestion that asks participants if 
they have had “t houghts that you would be better off dead, or of hurting yourself in some way” 
over the past two week s. For “in -person” research visits (i.e. , either on site or in the field where 
clinician assessment resources are reasonably available), any response other than “Not at all,” will prompt a clinician assessment for suicide risk and trigger a requirement for  the completion of 
the “in-person” version of the Mental Health Assessment form by [CONTACT_21118]. The Mental Health 
Assessment form documents the performance of the required direct clinician evaluation of the 
participant for suicide/homicide risk according to the site- specific SOP. This clinician evaluation 
should take place prior to the participant leaving the study site. A protocol deviation is required if 
the clinician evaluation is not completed prior to the participant leaving  the study site for in person 
research visits.  For participant research visits not  conducted in person or in a location that is 
physically remote from reasonably available clinician assessment resourc es, the “remotely” 
version of the Mental Health Assessment form should be completed to document provision of 
national or local mental health resource referral/contact [CONTACT_411100].  A protocol 
deviation is required if these referral/contact [CONTACT_411101]. The Mental  Health Assessment 
form is not completed when suicidality/homicidality is not endorsed on the respective Health 
Status  form questi on (e.g. spontaneously reported by a participant ). In these cases, the 
assessment of  reported suicidality/homicidality will be conducted in accordance with the study 
site’s standard of care  procedures . Consequently, all sites should monitor participant res ponses 
to the Health Status form, as well as  spontaneous expression of potential participant 
suicidal/homicidal ideation, and  have procedures in place to ensure participant  safety . 
Opi[INVESTIGATOR_411048]- fatal overdose events, healthcare utilization including ED visits and hospi[INVESTIGATOR_602],  
suicidal ideation, and all deaths including fatal overdoses will be tracked beginning at the time of 
consent and ending with participant study completion at the Day 30 visit.  Overdose events since 
enrollment will be captured by  [CONTACT_38767] -report, potentially collateral report (e.g., family), 
review of health records and EMS records (pending availability). In the event of F ull Study 
participant withdrawal/loss to follow -up and in the case of all Limited Study participants , we will 
attempt to track fatal overdose events and other mortality through Offices of Vital Statistics, 
Offices of the Certified Medical Examiner, and/or local morgues. Overdose events will be recorded on the Overdose Events and Risk Factors  form. Research  staff may become aware of safety 
events  in between study visits (i.e., via participant family and friends, ED visits, etc.). These non-
fatal events should be recorded on a study progress note to prompt data entry of the event at the 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518435]   January 15, 20 20 
 
42 
 RESEARCH STAFF TRAI NING  
Research staff will be trained as specified in the Study Training Plan developed by [CONTACT_200854], 
the CCC, the DSC, and other members of the Lead Team. Additional details and guidance for study procedures will be provided in a Manual of Operating Procedures (MOP) and in local SOPs. 
Research staff training will be conducted via in- person training sessions, webinar presentations, 
and/or telephone conferences. Required training will include Human Subjects Protection (HSP) and Good Clinical Practice (GCP) , as well as protocol -specific training as needed (e.g., 
assessments, safety procedures, data management and collection). Research staff collecting and entering data in Advantage eClinical will complete training on electronic case report form (eCRF) 
data entry, data management and integrity, and the Advantage eClinical data system. In- person 
practicums will be required of study staff conducting the recruitment, Informed Consent, urine 
drug screening, and the TLFB. All study staff will be required to complete the study -specific 
training plan for their assigned study role as well as satisfy any training requirements per local 
institutions.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518436]   January 15, 20 20 
 
43 
 STATISTICAL DESIGN AND ANALYSE S 
 General Design  
CTN -0079- A1 is an implementation study that will use mixed methods and triangulate 
multiple sources of data collected over the course of the parent (CTN -0079) and the ancillary 
studies to evaluate the feasibility, acceptability, sustainability, and impact of the ED -initiated BUP 
clinical program and implementation facilitation strategy and identify factors influencing diffusion 
and effectiveness. The ancillary study involves t hree phases of participation: 1) candidates for 
ED-initiated BUP  enrolled over a 1 2-month period (Post-IF and Maintenance periods, 6 months 
each ) to participate in two research visits (Days 0 and 30) and/or authorize administrative 
data matching, 2) ED staff, patients, and stakeholders’ participating in semi -structured 
qualitative inter views/focus groups at study close , and 3) retrospective chart review and data 
matching for all adult ED patients identified to have non -medical opi[INVESTIGATOR_411049], Post -IF or Maintenance periods.   
 Recruitment and E nrollment  
The ancillary study participants are planned to be identified from parent study sites: Catholic 
Medical Center, Valley Regional Hospi[INVESTIGATOR_307], and Be llevue/NYC Health and Hospi[INVESTIGATOR_600] . The study 
population will consist of ED patients who are candidates for ED -initiated BUP . We anticipate 
that, 300 ED patients (150 identified during each ancillary study period) will be found that meet 
this criterion . This is the population for evaluating the primary and key secondary implementation 
outcome s. Of those patients , approximately 120 ( i.e., 120/300=40% , with 60 participants enrolled 
during each ancillary study period) will enroll as F ull Study patient -participants. This is the 
population for  evaluat ing the primary and key secondary effectiveness outcomes. We also 
anticipate that as many as an additional [ADDRESS_518437] included an additional 20 Limited Study patient -participants in case this number is 
higher than anticipated for a total N=300 (120 + 180 + 20 ) for data matching outcomes.  Based on 
data from parent study, we approximate  40% to 90% of ED patients  that are eligible for and willing 
to receive ED-initiated BUP will actually receive it, and  40% to 80% of enrolled patient participants 
will be engage d in formal treatment within 30 days following ED discharge . Table 4 shows the 
expected cumulative number of individuals identified and those anticipated to receive ED -
initiated /expedited BUP for primary implementation outcome, as well as the number of individuals 
enrolled and engaged in formal treatment for primary effectiveness outcome. We present the 
number  of expected  ED-initiated/expedited BUP receivers and those engaged to formal treatment 
for the lowest and highest success rates  (i.e., 40% and 90% for primary implementation outcome , 
and 40% and 80% for primary effectiveness outcome). 
  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518438]   January 15, 20 20 
 
44 z Phase  Primary Implementation Outcome  
N=300  Primary Effectiveness Outcome  
N=120  
Number 
identified  
 Number who received 
ED-initiated/expedited 
BUP assuming, 40% - 
90% success rates Number 
enrolled  Number engaged in 
formal addiction 
treatment  for OUD , 
assuming 40% - 80%  
success rates  
40%  90%  40%  80%  
Post -IF Period        
1  25 10 23 10 4 8 
2  50 20 45 20 8 16 
3  75 30 68 30 12 24 
4  100 40 90 40 16 32 
5  125 50 113 50 20 40 
6  150 60 135 60 24 48 
 Maintenance 
Period        
1  175 70 158 70 28 56 
2  200 80 180 80 32 64 
3  225 90 203 90 36 72 
4  250 100 225 100 40 80 
5  275 110 248 110 44 88 
6  300 120 270 120 48 96 
Table 4: Expected cumulative numbers of individuals capable of being assessed for 
selected study milestones outcomes across Post -IF and Maintenance Periods by [CONTACT_411102] y Outcomes Measures  
 Definition of Primary Implementation Outcome  
The primary implementation outcome measure  is receipt of ED -initiated /expedited BUP. This is a 
binary outcome and will be defined as the proportion of ED patients receiving ED -
initiated /expedited  BUP  amongst ED patients who are candidates for ED -initiated BUP . 
Receipt of ED -initiated /expedited BUP will be operationally defined to include: (1) administration 
of BUP in the ED, (2) prescription for BUP as part of the ED visit, or (3) provision of a specific 
“warm” referral or transfer of care to a provider, clinic, or treatment setting with the capacity to 
administer or prescribe BUP within no more than [ADDRESS_518439] (EMR abstraction) and/or determined through 
research staff  assessments.  The outcome  will be calculated as a pooled success  rate over 
Post-IF and Maintenance periods.  
 Definition of Primary Effectiveness  Outcome 
The primary effectiveness outcome measure is engagement in formal addiction treatment for 
OUD on the 30th day following ED discharge. The primary effectiveness outcome is defined as : 
the proportion of participants who are confirmed to be engaged in formal addiction treatment for 
OUD on the 30th day following ED discharge, amongst participants who received ED -
initiated/expedited BUP . The outcome will be calculated as a pooled success rate over Post -IF 
and Maintenance periods.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518440]   January 15, 20 20 
 
45 
 Secondary Outcomes Measures  
[IP_ADDRESS]  Secondary Implementation Outcome Measures  
The key secondary implementation outcome measure is receipt of ED-initiated BUP.  This is a 
binary outcome and will be defined as the proportion of ED patients receiving ED -initiated  BUP 
amongst ED patients who are candidates for ED -initiated BU P. The outcome will be 
calculated as a pooled success rate over Post -IF and Maintenance periods.  
Other secondary Implementation outcomes will include other measures of reach, including 
evaluating ED -initiated BUP as a function of time. That is, evaluating the rate of ED -
initiated/expedited BUP provided via the ED over the course of the CTN -0079- A1 study with rates 
of ED-initiated BUP provision estimated secondarily. The  outcome measures are: (i)  rates of BUP 
provision between the Post -IF and Maintenance Periods and (ii) diffusion curves in which the 
number of patients provided BUP  is displayed graphically as a function of time . 
Other RE -AIM model dimensions to be assessed include: provider adoption measured by [CONTACT_411103] (i) provided BUP treatment and (ii) completed 
DATA 2000 training to become a BUP prescriber, and Implem entation fidelity (proportions for 
adherence to clinical actions associated with the delivery of ED -initiated BUP). Maintenance will 
be assessed by [CONTACT_411073] - and setting -level outcomes ≥ 6 months after the 
cessation of all study -supported IF (i.e., the Maintenance Period).  
[IP_ADDRESS]  Secondary Effectiveness Outcome Measures  
The key secondary effectiveness outcome is linkage to formal addiction  treatment for OUD within 
one week  (operationalized at within 7- 10 days). This is a binary outcome and will be defined as 
the proportion of participants with (objectively) confirmed linkage to formal addiction treatment for 
OUD within one week  following ED discharge, amongst participants who received ED -
initiated/expedited BUP. The outcome will be calculated as a pooled success rate over Post -
IF and Maintenance periods.  
Other s econdary effectiveness analyses will evaluate the participant subgroups who received ED -
initiated BUP and ED -expedited BUP separately as well as those who did not receive BUP.  
As in the parent study, a range of secondary effectiveness measures will be assessed at the index  
ED and Day 30 visits, including but not limited to:  
• Self-reported days of opi[INVESTIGATOR_74480] (TLFB)  
• UDS results at [ADDRESS_518441] index ED visit  
• Overdose events  
• Healthcare utilization  
• Quality of Life, Health, and Treatment Effectiveness ( PROMIS -29, PHQ -9, TEA)  
• Treatment satisfaction and acceptability  
Process measures related to the clinical protocol include but are not limited to:  
• Proportion of ED patients triaged who are screened for non -medical opi[INVESTIGATOR_2441]  
• Proportion of those screened who are positive for non -medical opi[INVESTIGATOR_2441]  
• Among those positive:  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518442]   January 15, 20 20 
 
46 - Proportion who are candidates to receive ED -initiated BUP  
- Proportion who receive ED -initiated BUP  (and whether via direct administration, 
prescription, and/or warm referral within 24 hours)  
- Numbers meeting inclusion/exclusion criteria for ED -initiated BUP  
- DSM -[ADDRESS_518443] 7 days  
- Not engaged in m edication treatment for OUD  
• Proportion who received facilitated referral for treatment amongst those who received 
some form of ED -initiated BUP . 
• Fidelity  
- Critical actions completed 
Implementation barriers and facilitators, include:  
• Stakeholder acceptability over time (key informant interviews, focus groups)  
• ED staff, patient , community barriers and facilitators (key informant interviews, focus 
groups)  
 Statistical Methods for Primary Analyses  
Primary and key secondary Implementation outcomes analyses will b e descriptive in nature, no 
inferential analysis will be performed.  The analyses will examine the overall implementation 
probabilities  (proportion s) across the Post -IF and the Maintenance Periods and calculate 
corresponding 95% confidence interval s. Analyses of the primary and key secondary 
effectiveness outcome s will follow the approach used for the primary and key secondary 
implementation outcomes. Each outcome will be presented as an  overall effectiveness 
probability  (proportion) across the Post -IF and Maintenance Periods, with a corresponding 95% 
confidence interval.  
 Precision Analyses for Primary Outcomes 
We assume that 300 ED patients (150 at each ancillary study period) identified uniformly across 
the 3 sites will be found to be candidates for ED-initiated BUP . This is the population for the 
denominator of the primary implementation outcome.  We also assume that , of these,  
approximately  120 participants will get enrolled in the F ull Study and become available to evaluate 
the effectiveness primary outcome.  Based on previous assumptions, and data from the parent 
study, we assume that the true proportion (success rate) of these individuals that actually receive 
ED-initiated BUP is between 40% to 90%, and the true proportion (success rate) of participants 
who were engaged in formal addiction treatment for OUD on the 30th day following ED discharge 
is between 40% to 80%.  
 Simulation Approach  
We investigated the bias and the distribution of t he widths of the 95% confidence intervals for the 
primary implementation outcome measure  (i.e., probability  of receiving ED -initiated/expedited 
BUP), and the primary effectiveness outcome measure (i.e., probability of engagement in formal addiction treatme nt for OUD on the 30
th day following ED discharge). The simulations were based 
on 10, [ADDRESS_518444] of site differences on the outcome measures (site 
variability)  of: Δ= (0,0.1,1,2,3)  and the success rates ( p) = (0.4,0.5,0.6,0.7,0.8,0.9)  for the 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518445]   January 15, 20 20 
 
47 implementation outcome and the success rate s (p) = (0.4,0.5,0.6,0.7,0.8)  for the effectiveness 
outcome . We investigated the 95% con fidence interval widths for N=180, N=240 and N=300 for 
the primary implementation outcome and N=60, N=90 and N=[ADDRESS_518446] -IF and Maintenance periods, we take the implementation 
probability estimate for that site to be 𝛼𝛼 /(𝛼𝛼+𝛽𝛽), with estimated variance 𝛼𝛼
𝛽𝛽/[(𝛼𝛼+𝛽𝛽)2(𝛼𝛼+𝛽𝛽+
1)], where 𝛼𝛼=𝑆𝑆+ 1 and 𝛽𝛽=𝐹𝐹+ 1. We take the overall site success rate estimate to be the 
average of the three site- level estimates. Because the site- level estimates are independent, the 
variance of the overall estimate is the sum of the site -level variances divided by 9. To construct 
confidence limits, we assume the overall estimate is roughly normal in distribution, with upper and 
lower 95% confidence intervals given by ±1. 96∗ √𝑉𝑉𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 . An exception to this is that we did not 
allow confidence limits to stray outside (0,1). Same simulation approach was used for primary 
effectiveness outcome precision analyses . 
Simulation SAS code 
SAS code to perform this calculation is below. We assume the results of the trial are in file SIMUL, 
where there is one record per patient, with variables Y, site, and phase, where:  
• y = 1 if the ED -BUP was implemented for this patient, and 0 otherwise  
• site = 1, 2, or 3, depending on the site of the patient  
• phase = [ADDRESS_518447] -IF period and phase=2 if the patient was 
ident ified during the Maintenance period.  
• The outcome of the calculations is in file EST, where:  
• (e1, e2, e3) are the site- specific estimates of the implementation probabilities across Post -
IF period and Maintenance period  
• (v1, v2, v3 ) are the estimated variances for ( e1, e2 , e3) 
• (pest) is the estimated implementation probability  across Post -IF period and Maintenance 
period 
• (lclest, uclest ) is the corresponding 2 -tailed 95% confidence limit . 
 
proc summary nway data = SIMUL ;  
 class site;  
 var y;  
 output out = summ sum=;  
 run; 
 
data summ;  
 set summ;  
 heads = y;  
 tails = _freq_- y; 
 alpha = heads+1;  
 beta = tails+1;  
 e = alpha / (alpha + beta);  
 v = alpha * beta / ((alpha + beta)**2 * (alpha + beta + 1));  
 keep heads tails e v;  
 run; 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518448]   January 15, 20 20 
 
48  
%macro t(what);  
 proc transpose data = summ out = tsumm&what prefix = &what;  
   var &what;  
   run; 
 %mend t;  
 
%t(e);  
%t(v);  
 
data est;  
 merge tsumme tsummv;  
 /* intentional merge without BY [INVESTIGATOR_150313] */  
 drop _name_;  
 pest = (e1 + e2 + e3 )/3; 
 vest = 1/9 * (v1 + v2 + v3 ); 
 lclest  = min (1, max (0, pest - 1.96 * sqrt( vest))); 
 uclest  = max (0, min (1, pest  + 1.96 * sqrt( vest))); 
 ciwidth = uclest - lclest; 
 run;  
 
The s ame SAS code was used for the primary effectiveness outcome precision analyses .  
  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518449]   January 15, 20 20 
 
49 
 Simulation Results  
Below we present the 90th percentile of the distribution of the 95% confidence interval widths and 
the bias for the implementation and effectiveness probabilities  across Post -IF and Maintenance  
periods. Figures 2-3 present plots for the implementation probabilit y and 3-4 present plots for the 
effectiveness probabilit y.  
 
Figure 2: 90th percentile for the 95% confidence interval widths of the estimate of implementation success 
rate as a function of the true value ( p) for given site variability, delta ( Δ) and sample size, N . 
 
  300 240 180 Npciwidthdelta = 3 delta = 2delta = 1 delta = 0.1 delta = 0
0.4 0.5 0.6 0.7 0.8 0.9 0.4 0.5 0.6 0.7 0.8 0.9 0.4 0.5 0.6 0.7 0.8 [IP_ADDRESS].[IP_ADDRESS].[IP_ADDRESS].40.[ADDRESS_518450]   January 15, 20 20 
 
50  
Figure 3: Mean bias for implementation success rate as  a function of the true value ( p) for given site 
variability, delta ( Δ) and sample size, N . 
 
 300 240 180 Nppbiasdelta = 3 delta = 2delta = 1 delta = 0.1 delta = 0
0.4 0.5 0.6 0.7 0.8 0.9 0.4 0.5 0.6 0.7 0.8 0.9 0.4 0.5 0.6 0.7 0.8 0.9-0.10-[IP_ADDRESS].10-0.10-[IP_ADDRESS].[ADDRESS_518451]   January 15, 20 20 
 
51  
Figure 4: 90th percentile for the 95% confidence interval widths of the estimate of effectiveness  success 
rate as a function of the true value ( p) for given site variability, delta ( Δ) and sample size, N . 120 90 60 Npciwidthdelta = 3 delta = 2delta = 1 delta = 0.1 delta = 0
0.4 0.5 0.6 0.7 0.8 0.4 0.5 0.6 0.7 0.8 0.4 0.5 0.6 0.7 [IP_ADDRESS].[IP_ADDRESS].[IP_ADDRESS].40.[ADDRESS_518452]   January 15, 20 20 
 
52  
Figure 5: Mean bias for effectiveness  success rate as a function of the true value ( p) for given site variability, 
delta (Δ) and sample size, N .  
 Summary of Precision Analyses  
For all the simulat ion scenarios investigated for primary implementation and effectiveness 
outcomes , the 90th percentiles of the 95% confidence interval widths seem  to decrease with 
increase in site differences and are relatively lower for larger sample size; the planned sample 
sizes of N=300 (ED patients) and N=120 (participants), but are all  below 0.2 and 0.3 for 
implementation and effectiveness probabilities, respectively. This means for each scenario 
investigated, 90% of the confidence interval widths are less than 0.[ADDRESS_518453] small bias and capture the true outcomes with high precision.  
 Secondary Analysis  
Secondary implementation outcomes will be analyzed using descriptive statistics such as 
proportions, counts/frequencies with 95% confidence intervals  and univariate tests like Chi-
Square/Fisher exact test  t-test and nonparametric tests , where appropriate . Similarly, secondary 120 90 60 Nppbiasdelta = 3 delta = 2delta = 1 delta = 0.1 delta = 0
0.4 0.5 0.6 0.7 0.8 0.4 0.5 0.6 0.7 0.8 0.4 0.5 0.6 0.7 0.8-0.10-[IP_ADDRESS].10-0.10-[IP_ADDRESS].[ADDRESS_518454]   January 15, 20 20 
 
53 effectiveness  outcomes will be analyzed using appropriate summary statistics and univariate 
tests. Statistical models such as Generalized Linear Models (GLM) and Generalized Estimating 
Equations (GEE) with appropriate distributions and link functions , and Linear Mixed Models 
(LMM)  may be used to analyze some secondary outcome measures where appropriate.  
 Tertiary and Exploratory Analysis  
These will include (1) evaluating implementation and effectiveness outcomes over the course of 
the CTN -[ADDRESS_518455] ing comparisons between 
each of the defined 6- month Implementation (i.e. , parent study), Post -IF, and Maintenance 
Periods for which comparable data exists ; (2) Testing several permutations of the primary 
implementation and effectiveness outcomes. For example, (i) permutations of how the numerator 
or denominator are defined and how these data are collected for the primary implementation 
outcome s (e.g., excluding referrals; including only patients identif ied through EM R 
documentation) (ii) permutations to effectiveness outcomes and analyses will include evaluation 
of linkage and engagement over different timeframes (e.g., linkage within 72 hours, 14 days, and 
30 days; time -to-event analyses), evaluating alternative denominators (e.g., including participants 
who did not receive ED -initiated BUP), and alternate means of how these data are captured and 
defined (e.g., claims and other administrative data). Other analyses will include comparing the 
agreement of quality measures assessed using administrative data to the gold standard data 
collected through the clinical research assessments and identifying patient -level characteristics 
as well as structural and process measures associated with measure completion and 
effectivenes s. See section 8.3 for more details on tertiary and exploratory outcomes. 
Analyses of tertiary and exploratory outcomes may use the same  approaches  used for primary 
and secondary outcomes.  Additionally, time -to-event analyses may  be conducted for linkage and 
engagement time- to-event outcomes.  
 Significance Testing  
Analyses for primary implementation and effectiveness analyses are descriptive in nature hence 
no anticipated adjustment for multiple testing. Likewise, n o adjustments for m ultiple comparisons 
for the secondary and exploratory analyses as this is a feasibility  study . Instead, the type I error 
rate will be controlled at 5%  for all statistical testing . 
 Interim Analysis  
Interim analysis will be conducted at the end of  the Post -IF P eriod to determine if the study should 
proceed as planned - without additional I F support  – into the Maintenance P eriod. The analysis 
will be conducted by [CONTACT_411104] -initiated BUP during the parent study 
enrollment period and the Post -IF period of the ancillary study . The ED -initiated BUP measure 
will include BUP administered or prescribed in the ED, as warm handoffs to BUP treatment within [ADDRESS_518456]-IF period is <25% of that observed during the parent study with the qualification that warm 
handoffs to a BUP provider for treatment within [ADDRESS_518457] the analysis and change the conclusion. If failed sustainability is met, the study team will resume IF support at the 
site(s) and data collection and enrollment will continue; however, by [CONTACT_108], it will no longer be 
considered a Maintenance P eriod. As such, statistical analyses and reporting would be amended 
accordingly.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518458] to follow -up after receiving 
ED-BUP will be counted as not linked or engaged (failure) in treatment instead of generating 
missing data. Sensitivity analyses may be conducted whereby [CONTACT_411105] -up after 
receiving ED -BUP will be counted as missing data and the results compared with the above 
approach where such cases are considered as failure. 
Several strategies will be implemented to minimize the likelihood and the rate of potential missing 
data in the proposed study. Timely data entry combined with frequent, planned, and scheduled 
evaluation of data completeness reports will trigger protocols for tracking and obtaining missing data.  
 Demographic and Baseline Characteristics  
Participants’ and ED providers’ baseline demographics and characteristics will be presented using 
summary statistics. D istribution s of continuous variables will be presented with mean and 
standard deviation. Categorical variables will be summarized in terms of frequencies/counts and 
percentages.  
 Safety Analysis  
The following events will be summarized by [CONTACT_3725]: opi[INVESTIGATOR_2480] -related overdose events , healthcare 
utilization including ED visits and hospi[INVESTIGATOR_602], suicidal ideation, and death events . The 
assessment period for these events will begin at the time of participant consent and end with 
participant study completion at the Day 30 visit . 
 Qualitative S tatistical Analyses  
We will utilize the Rapid Assessment Process [15] a type of participatory action research using 
intensive, team interaction and multiple cycles of data collection followed by [CONTACT_411106]. It is estimated that 2-3 events, either by [CONTACT_411107],  will occur 
until themes begin to repeat.  
Using directed content analysis [29], transcripts will be independently reviewed, coded and 
analyzed by a multi -disciplinary group. Initially transcripts will be individually reviewed line by [CONTACT_411108]. Following the coding of the initial 
set of transcripts, the qualitative research team will meet to review the initial coding scheme and a codebook will be generated by [CONTACT_21128], which will contain operational definitions for each 
code. Code generation will be iterative and the codebook subject to change until no new codes 
are identified. Common patterns across the dataset will be identified and will be grouped into 
themes. Analysis will use  the PARiHS framework, which examines the interaction between three 
key elements of Evidence, Context and Facilitation, and including sub-elements of patient and 
clinical experience (communication, knowledgeable and empathetic providers), receptive context (resources to provide addiction treatments), and culture (value of  team -based approach) . An audit 
trail will be maintained. Data will be entered into and organized using Atlas.ti software.  Participant 
feedback on analysis will be sought in follow -up interviews to enhance the validity of our findings.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518459]   January 15, 20 20 
 
56 
 REGULATORY COMPLIANCE AND SAFETY 
 Statement of Compliance  
This trial will be conducted in accordance with the current version of the protocol, in full conformity 
with the ethical principles outlined in the Declaration of Helsinki, the Protection of Human Subjects described in the International Council for Harmonisation Good Clinical Practice (GCP) Guidelines, 
applicable [LOCATION_002] (US) Code of Federal Regulations (CFR), the NIDA Terms and 
Conditions of Award, and all other applicable state, local, and federal regulatory requirements. 
The Principal Investigator [INVESTIGATOR_7433], or changes to the protocol will take 
place without prior agreement from the Sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial 
participants. An Operations Manual will be provided as a reference guide and study quality 
assurance tool.   
 Institutional Review Board Approval  
The Biomedical Research Alliance of [LOCATION_001] (BRANY) will be the IRB of record for the protocol 
and will provide study oversight in accordance with [ADDRESS_518460] entered into reliance/authorization agreements for 
Protocol CTN -0079- A1. BRANY IRB will follow written procedur es for reporting its findings and 
actions to appropriate officials at each participating institution. Some sites may meet Exception 
Criteria to the NIH single IRB Policy and may not utilize the IRB of Record.  
Prior to initiating the study, participating si te investigators will obtain written approval from the 
Ethics Review Committee (ERC) or Institutional Review Board (IRB) to conduct the study at their 
respective site, which will include approval of the study protocol. If changes to the study protocol 
become necessary, protocol amendments will be submitted in writing by [CONTACT_411109]. In addition, IRBs will approve all consent forms, recruitment 
materials, and any materials given to the participant, and any changes made to these documents 
throughout study implementation. Approval of both the protocol and the consent form(s) must be obtained before any participant is consented. For changes to the consent form, a decision will be 
made regarding whether previously consented participants need to be re- consented. IRB 
continuing review will be performed annually, or at a greater frequency contingent upon the complexity and risk of the study. Each site principal investigator [INVESTIGATOR_411050], IRB -approved consent documents, and approval for all 
protocol modifications. These materials must be received by [CONTACT_411110]. Unanticipated 
problems involving risk to study participants will be promptly reported to and reviewed by [CONTACT_411111], according to its usual procedures.  
 Informed Consent  
The informed consent process is a means of providing study information to each prospective 
participant and allows for an informed decision about participation in the study. Informed consent 
continues throughout the individual’s study participation.  
The written informed consent form for Full Study participants will include all the required elements 
of informed consent and may contain additional relevant consent elements and NIDA CCTN 
specific additional elements. Each study site must have all study informed consent forms (written 
and verbal) approved by [CONTACT_60683]. Prior to initial submission to the IRB and with each 
subsequent consent revision, the consent form(s) must be sent to the Clinical Coordinating Center 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518461]   January 15, 20 20 
 
57 (CCC) and the Lead Node (LN) to confirm that each consent form contains the required elements 
of informed conse nt as delineated in 21 CFR 50.25(a) and CFR 46.116(b), as well as pertinent 
additional elements detailed in 21 CFR 50.25(b) and 45 CFR 46.116(c) and any applicable CCTN requirements . Every study participant is required to sign a valid, IRB- approved current  version of 
the study informed consent form , or for Limited Study Participants, a signed, Information Sheet, 
in addition to study -specific Release of Information form prior to the initiation of any study related 
procedures. Every Limited Study participant will be presented with an Information Sheet to be 
reviewed and signed prior to participation. The site must maintain the original signed the 
applicable consent  documents (i.e., ICF, Information Sheet ) for every participant in a locked, 
secure location that  is in compliance with all applicable IRB and institutional policies and that is 
accessible to the study monitors. Note: Authorization is embedded within the Informed Consent form and the Information Sheet. Every focus group and qualitative interview parti cipant will 
verbally consent to participation. Each participating site will request a Waiver of Documentation 
of Informed C onsent.  
During the informed consent process, research staff will explain the study to the potential 
participant and provide the potential participant with a copy of the informed  consent form to read 
and keep for reference. All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study and their righ ts as 
research participants. Extensive discussion of risks and possible benefits will be provided to the participants. Participants will have the opportunity to carefully review the written informed consent form and ask questions prior to signing. The part icipants should have the opportunity to discuss 
the study with their family and close friends or think about it prior to agreeing to participate. If the participant is interested in participating in the study, a qualified staff member will review each 
section of the IRB -approved informed consent form in detail and answer any questions the 
participant may pose. The participant will consent by [CONTACT_200874]. The person obtaining consent and a witness, if required by [CONTACT_60683], will also sign and 
date the consent document. It is strongly recommended that another research staff member review the consent after it is signed to ensure that the consent is properly executed and complete. 
Staff members delegated by [CONTACT_7880] [INVESTIGATOR_411051] (DoR) Log and must be approved by [CONTACT_1201], if 
required. All persons obtaining consent must have completed appropriate GCP and HSP training, as mandated by [CONTACT_268634]. 
The informed consent form must be updated or revised whenever important new safety 
information is available, or whenever the protocol is amended in a way that may affect participants’ 
participation in the trial. The rights and welfare of the participants will be protected by [CONTACT_411112]. The participant will be informed that their participation is voluntary and  
they may withdraw from the study at any time, for any reason without penalty. Individuals who refuse to participate or who withdraw from the study will be treated without prejudice. Study sites 
will be responsible for maintaining signed consent forms as s ource documents for quality 
assurance review and regulatory compliance. 
Each participating site will request a Waiver of Informed Consent/HIPAA authorization from the 
IRB of record for the abstraction of data from the medical record  and for the linking of these patient 
data to registry, administrative and claims data . Each participating site will request a Waiver of 
Documentation of Informed Consent for the completion of the ED Health Survey . 
In accordance with applicable federal regulations (45 CFR 46.116(f)), the study protocol meets 
the following required criteria as defined in 45 CFR 46.116(f)(3)): 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518462]   January 15, 20 20 
 
58 • The research involves no more than minimal risk to the subjects;  
• The research could not practicably be carried out without the requested waiver or 
alteration;  
• If the research involves using identifiable private information or identifiable biospecimens, the research could not practicably be carried out without using such information or 
biospecimens in an identifiable format; 
• The waiver or  alteration will not adversely affect the rights and welfare of the subjects; 
and, 
• Whenever appropriate, the subjects or legally authorized representatives will be provided with additional pertinent information after participation.  
The study does not preempt any applicable federal, state, or local laws which require additional information to be disclosed in order for informed consent to be legally effective. It is in 
conformance with [ADDRESS_518463], (as applicable), for further review.  
 Participant and Data Confidentiality  
Participant confidentiality and privacy  are strictly held in trust by [CONTACT_3486], 
their staff, the safety and oversight monitor(s), and the sponsor(s) and funding agency, and will 
be maintained in accordance with all applicable federal regulations and/or state/Commonwealth 
law and regulations. This confidentiality is extended to the data being collected as part of this 
study. Data that could be used to identify a specific study participant will be held in strict 
confidence within the research team. No personally -identifiable information from the study will be 
released to any unauthorized third party without prior written approval of the sponsor/funding agency and the participant.  
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representatives of the sponsor or funding agency, 
representatives of the Institutional Review Board (IRB), regulatory agencies or representatives 
from companies or organizations supplying the product, may inspect all documents and record s 
required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
Participant records will be held confidential by [CONTACT_9909], secure storage of any documents that have participant identifiers, and secure 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518464]   January 15, 20 20 
 
59 computing procedures for entering and transferring electronic data. The study part icipant’s 
contact [CONTACT_10414]. 
At the end of the study, all records will continue to be kept in a secure location for as long a period as denoted in Section 13.8, Records Retention and Requirements.  
By [CONTACT_200877], the investigator affirms that information furnished to the 
investigator by [CONTACT_200878]/Privacy Board, Ethical Review Committee, or similar expert committee; affiliated institution; 
and employees only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees.  
 Certificate of Confidentiality  
To further protect th e privacy of study participants, the Secretary, Health and Human Services 
(HHS), has issued a Certificate of Confidentiality (CoC) to all researchers engaged in biomedical, 
behavioral, clinical or other human subjects research funded wholly or in part by t he federal 
government. Recipi[INVESTIGATOR_240553] (see https://humansubjects.nih.gov/coc/index
). This protects participants from disclosure of sensitive 
information (e.g., drug use).  It is the NIH policy that investigators and others who have access to 
research records will not disclose identifying information except when the participant consents or 
in certain instances when federal, state, or local law or regulation requires disclosure. NIH expects 
investigators to inform research participants of the protections and the limits to protections 
provided by a Certificate issued by [CONTACT_17355].  
 Health Insurance Portability and Accountability Act (HIPAA)  
Study sites may be required by [CONTACT_344100]. Sites will be respons ible for communicating with the IRB(s) or 
Privacy Board(s)  of record and obtaining the appropriate approvals or waivers to be in regulatory 
compliance. Releases of participant identifying information that are permitted by [CONTACT_9911], but which are prohibited by [CONTACT_9912]/or state/Commonwealth law and regulation, are prohibited.  
 Investigator Assurances  
Each research site must file (or have previously filed) a Federal Wide Assurance (FWA) with the 
HHS Office for Human Research Protection setting forth the commitment of the organization to 
establish appropriate policies and procedures for the protection of human research subjects in 
alignment with 45 CFR 46, Subpart A , with documentation sent to NIDA or its designee. Research 
covered by [CONTACT_362572] (45 CFR 46.103 ).Prior to initiating the study, the PI [INVESTIGATOR_200761] a protocol signature 
[CONTACT_3264], and investigator agreement , providing assurances that the study will be performed 
according to the standards stipulated therein.  
 Financial Disclosures  
All investigators will comply with the requirements of [ADDRESS_518465] monitors who will examine whether study 
procedures are conducted appropriately,  and that study data are generated, documented and 
reported in compliance with the protocol, GCP, and applicable regulations. These monitors will audit, at mutually agreed upon times, regulatory documents, case report forms (CRFs), informed 
consent forms and corresponding sourc e documents for each participant. Monitors will have the 
opportunity and ability to review any study -associated document or file.  
NIDA -contracted monitors will assess whether submitted data are accurate and in agreement wit h 
source documentation and will also review regulatory/essential documents such as correspondence with the IRB  of record . Areas of particular concern will be participant informed 
consent forms, protocol adherence, reported safety events and corresponding assessments, and 
principal investigator [INVESTIGATOR_411052] . Reports will be prepared following 
the visit and forwarded to the site principal investigator, the L ead Investigator  (LI) and NIDA 
CCTN.  
Qualified Node personnel  (Node QA monitors ) or other designated party(ies ) may provide site 
management for each site during the trial. Node QA  staff or other designated party(ies ) will audit 
source documentation, including informed consent forms and HIPAA forms. This will take place as specified by [CONTACT_9920], Node PI [INVESTIGATOR_200763], detect, and correct problems at the study sites. Node QA  personnel  will verify 
that study procedures are properly followed and that site personnel are trained and able to conduct the protocol appropriately. If the node personnel ’s review of study documentation 
indicates that additional training of site study personnel is needed, n ode QA personnel  will 
undertake or arrange for that training. Details of the contract, N ode QA and data monitoring are 
found in the study Quality Assurance (QA) monitoring plan.  
 Special Populations to Consider  
 Inclusion of Women and Minorities  
The study sites should aim and take steps to enroll a diverse study population. If difficulty is encountered in recruiting an adequate number of women and/or minorities, the difficulties involved 
in recruitment will be discussed in national conference calls and/or face- to-face meetings, 
encouraging such strategies as linkages with medical sites and/or treatment programs that serve a large number of women and/or minorities, advertising in newspapers or radio stations with a high female/minority readership/listening audience, etc. 
 Prisoner  Certification   
As per 45 CFR 46 Subpart C, there are additional protections pertaining to prisoners as study 
participants. A prisoner is defined as any individual involuntarily confined or detained in a penal 
institution. The term is intended to encompass individuals sentenced to such an institution under a criminal or civil statute, individuals detained in other facilities by [CONTACT_411113] a penal 
institution, and individuals detained pending arraignment, trial, or sentencing. In order to meet these additional protections, the study team will obtain certification from the Office for Human 
Research Pr otections (OHRP) to follow -up with participants who become prisoners during the 
course of the study, as necessary.  
Approval from the Office for Human Research Protections ( OHRP ) to include prisoners  at the time 
of the Day [ADDRESS_518466]   January 15, 20 20 
 
61 Data may be collected either in person, by [CONTACT_648], in writing, and/or by [CONTACT_10075], provided 
that data collection follows the procedures approved by [CONTACT_411114] . Details of 
the nature of the research will not be shared with staff at the jail/prison, and visits, whether in person or by [CONTACT_648], will only be conducted if the participant ’s confidentiality can be maintained 
and no audio- tapi[INVESTIGATOR_4095] . Study participation will have no effect on the participant ’s jail/prison 
sentence, nor potential probation or parole. 
 Employees  
The study will include employees of the sites  and local community treatment programs . A subset 
of those meeting eligibility criteria will be invited to partic ipate. Extra caution will be taken  to ensure 
participants are neither pressured nor coerced. Declination to participate will not affect their 
careers and credits.  
 Regulatory Files  
The regulatory files should contain all required regulatory documents, study -specific documents, 
and all important communications. Regulatory files will be checked at each participating  site for 
regulatory document compliance prior to study initiation, throughout the study, as well as at study 
closure.  
 Records Retenti on and Requirements  
Research records for all study participants (e.g., case report forms, source documents, signed 
consent forms, audio and video recordings, and regulatory files) are to be maintained by [CONTACT_1031] a secure location for a minimum of [ADDRESS_518467] or outcome of the trial or increase risk to study participants. Safety reporting will occur 
as previously described. At the completion of the trial, the LI  will provide a final report to the 
Sponsor.  
 Audits  
The Sponsor has an obligation to ensure that this trial is conducted according to good clinical research practice guidelines and may perform quality assurance audits for protocol compliance. 
The LI  and authorized staff from the National Lead Study Team; the National Institute on Drug 
Abuse Clinical Trials Network (NIDA CTN, the study sponsor); NIDA’s contracted agents, monitors or auditors; and other agencies such as the Department of Health and Human Serv ices 
(HHS), the Office for Human Research Protection (OHRP) and the Institutional Review Board of record may inspect research records for verification of data, compliance with federal guidelines 
on human participant research, and to assess participant safety.  
 Study Documentation  
Each participating site will maintain appropriate study documentation (including medical and 
research records) for this trial, in compliance with ICH E6 R2 and regulatory and institutional 
requirements for the protection of confidentiality of participants. Study documentation includes all 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518468]   January 15, 20 20 
 
62 case report forms ( CRFs ), workbooks, source documents, monitoring logs and appointment 
schedules, sponsor -investigator correspondence, and signed protocol and amendments, Ethics 
Review Committee or IRB correspondence and approved consent form s (written and verbal) and 
signed participant consent forms. As part of participating in a NIDA -sponsored study, each site 
will permit authorized representatives from NIDA and regulatory agencies to examine (and when 
permitted by [CONTACT_2371], to copy) clinical records for the purposes of quality assurance reviews, audits, 
and evaluation of the study safety, progress, and data validity.  
Source documents include all recordings of observations or notations of clinical activities and all 
reports and records necessary for the evaluation and reconstruction of the clinical research study. 
Whenever possible, the original recording of an observation should be retained as the source document; however, a photocopy is acceptable provided that it is a clear, legible, and an exact 
duplication of the original document.  As per Section 10.[ADDRESS_518469] practices and ethical guidelines and organized under the following four 
principles or parameters : 1) security of the data; 2) confidentiality of information contained in the 
data; 3) permission to use data for research purposes; and 4) appropriate/ethical use of the data 
by [CONTACT_41314]. [11, 30]  We will secure data in accordance with applicable laws (e.g., HIPAA, 
CFR 42 Part 2,)  establish security protocols based upon industry standards, summarized by 
[CONTACT_411115][31]  University or the 
System Administration, Networking and Security Institute (SANS Institute). [32] The security plan 
include (1) well -trained staff, ensuring that all people who have access to, or can grant access to, 
sensitive data must understand the risks involved with disclosure of information and have the expertise to secure the data. Second, we will establish well -crafted policies and procedures that 
provide clear processes for  ensuring that data are secure based on available models for security 
guidelines and poli cies (e.g., SANS Institute) . Third, in consultation with experts to confirm current 
options and industry standards, we will use technological safeguards, including data encry ption, 
secure network controls (e.g., logged firewalls, two-factor access protocols).  
It is of critical importance to ensure patients’ rights to privacy and confidentiality are appropriately 
preserved and that permissions are secured when linking patient -level data to administrative data, 
particularly data related to substance use services (with the added protections under CFR 42 Part 2). As such, prior to linking  data with covered entities , we will establish data usage agreements 
and will maintain strict adherence to legal and ethical standards and best practic es. 
We will obtain appropriate permissions to retain, access, and use administrative data. We will 
make a formal and detailed request for data from the data owner/custodian. This request will include things such as an introduction to the study, a list of needed variables, timespan and 
population parameters for the data, transfer media/methods, and a checklist for owner/custodian 
staff to follow to ensure better accuracy of data extraction. The written agreement with the data 
owner/custodian will clarify the terms of data possession and what analyses and studies are 
allowed using the data, how the data will be secured and confidentiality maintained, whether additional permissions or consent will be required at an individual level, and how long we may retain t he data. The agreement will also address with whom we may share the data (if anyone).  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518470] to some 
modifications, a general overview of the data sharing/linkage process is as follows. We (study 
coordinators/staff) will create a data set containing the identifiers necessary for the match (name, 
DOB, sex/gender, medical record number, etc.) as well as a unique identifier  for patients who 
present to the EDs who are identified to have opi[INVESTIGATOR_2441]. As it is not feasible to contact [CONTACT_411116], particularly among 
individuals without stable phone access or addresses, we request a waiver of consent . Through 
this waiver, we will share this data set with the covered entity that is the owner/custodian, which 
will include but not be limited to the NH DHHS and NYU HEAL . In accordance with the data use 
agreement , they will use the data set to perform the match with Medicaid claims (and  potentially 
other  administrative data, pending availabi lity) and/or grant permission to a study staff/ data 
analyst to perform the match.  The identifiers contained in the original data set (name, DOB, etc.) 
with the exception of the unique identifier , will be expunged from the new data set and not re -
linked by [CONTACT_3476].  Administrative data will, however, be linked through the unique identifier  
to the assessments, outcomes, and other data of the Limited Study and Full Study participants 
who provided individual written authorization. 
The administrative data matching will allow us  to evaluate outcomes for the larger population of 
patients who present to the ED with OUD . It is essential to evaluate the entire population of 
patients with untreated OUD to ensure equity in the larger effort to improve quality of care and 
treatment outcomes at the population level. It is well -aligned with our overall goal to inform the 
development and improve the effectiveness and reach of programs that identify and initiate treatment of OUD in EDs in a way that is generalizable to support population- level health quality 
improvement and treatment outcomes.  
 Protocol Deviations  
This protocol defines a protocol deviation as any noncompliance with the clinical trial protocol. 
The noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions will be developed by [CONTACT_48162].  
These practices are consistent with ICH GCP:  
• Section 4.5 Compliance with Protocol, subsections 4.5.1, 4.5.2, and 4.5.3  
• Section 5.1 Quality Assurance and Quality Control, subsection 5.1.1  
• Section 5.20 Noncompliance, subsections 5.20.1, and 5.20.2.  
Any departure from procedures and requirements outlined in the protocol will be classified as 
either a major or minor protocol deviation. The difference between a major and minor protocol 
deviation has to do with the seriousness of the event and the corrective action required. A minor 
protocol deviation is considered an action (or inaction) that by [CONTACT_411117], rights, or welfare of a study 
participant. Major protocol deviations are departures that may compromise the participant safety, 
participant rights, inclusion/exclusion criteria or the integrity of study data and could be cause for 
corrective actions if not rectified or prevented from re- occurrence. Sites will be responsible for 
developi[INVESTIGATOR_9818]. Those corrective action plans may be reviewed/approved by [CONTACT_200885]. All protocol deviations will be monitored at each site for 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518471]   January 15, 20 20 
 
64 (1) significance, (2) frequency, and (3) impact on the study objecti ves, to ensure that site 
performance does not compromise the integrity of the trial.   
All protocol deviations will be recorded in the Electronic Data Capture (EDC) system via the 
Protocol Deviation CRF. The CCC, DSC and the LI must be contact[CONTACT_411118].  
Additionally, each site is responsible for reviewing the IRB of record’s definition of a protocol 
deviation or violation and understanding which events need to be reported. Sites must  recognize 
that the CTN and IRB definition of a reportable event may differ and act accordingly in following 
all reporting requirements for both entities.   
 Safety Monitoring  
The LI may appoint a Site Medical Clinician (MD, DO, NP, or PA) for this study, who will review or provide consultation for each Safety Event and Serious Adverse Event (SAE) as needed. 
Adverse Events (AEs) other than defined Safety Events will not be tracked or reported. For the 
purposes of this protocol, the only S AEs that will be tracked, reviewed, and reported are those 
associated with death, which will  include any participant death occurring during the study or which 
comes to the attention of the study staff during the protocol -defined follow -up period, whether or 
not considered caused by [CONTACT_34144]. These reviews will include an assessment of the 
possible relatedness of the event to the study intervention or other study procedures. The Site 
Medical Clinicia n will also provide advice for decisions to exclude, refer, or withdraw participants 
as required. In addition, A Safety Monitor/Medical Monitor will be assigned to independently 
review the safety data, present it to the DSMB for periodic review, and provide PIs a Safety Letter when necessary. The Safety Monitor/Medical Monitor will determine which safety events require 
expedited reporting to NIDA, the DSMB and regulatory authorities. This will include events that 
are serious, related and unexpected. The study staff will be trained to monitor for and report Safety 
Events  and death -related SAEs.  
Each of the sites has established practices for managing medical and psychiatric emergencies, 
and the study staff will continue to utilize these procedures. Treatment providers at each site will 
be responsible for monitoring participants for possible clinical deterioration or other problems, and for implementing appropriate courses of action. 
 Data and Safety Monitoring Board (DSMB)  
An independent CTN DSMB will examine accumulating data to assure protection of participants’ 
safety while the study’s scientific goals are being met. The CTN DSMB is responsible for 
conducting periodic reviews of accumulating safety  and efficacy data . It will determine whether 
there is support  for continuation of the trial, or evidence that study procedures should be changed, 
or if the trial should be halted, for reasons relating to the safety of the study participants , the 
efficacy of treatment under study, or inadequate trial performance (e.g., poor recruitment).  
 Safety Monitor/Medical Monitor  
The CCC Safety Monitor/Medical Monitor is responsible for reviewing all Safety Events  and death -
related serious adverse events reported. All death- related SAEs will be reviewed within one 
business day of  being reported in the eClinical. The Safety Monitor/ Medical Monitor will also 
indicate concurrence or not with the details of the report provided by [CONTACT_779]. Where further 
information is needed, the Safety M onitor/Medical Monitor will discuss the event with the site. 
Reviews of death- related SAEs will be conducted in the Advantage  eClinical data system and will 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518472]   January 15, 20 20 
 
65 be a part of the safety database. All Safety Events  are reviewed on a regular  basis to observe 
trends or unusual events.  
The CCC Safety Monitor/Medical Monitor will in turn report events to the sponsor and regulatory 
authorities if the event meets the definition of an expedited event. Reports will be generated and presented for Dat a Safety Monitoring Board (DSMB) meetings.  
 Safety Events  
Because this prospective study will examine BUP treatment initiation and the impact of ED -
initiated BUP on engagement in addiction treatment and drug- use-related outcomes, and the use 
of these medications is in line with community practice, safety reporting will be limited to recording 
any opi[INVESTIGATOR_411053], any death, suicidal ideation, and healthcare utilization 
including ED visits and hospi[INVESTIGATOR_602]. Deaths will be reported on the adverse/serious adverse 
event form set. The other Safety Events will be reported on study specific forms.  
For the purpose of this study, the following events will not be reported as SAE s but will instead 
be reported on study -specific forms. These events will be reported to the single IRB (and any local 
IRB(s ), if applicable) per IRB guidelines:  
• Opi[INVESTIGATOR_46211] (not resulting in death)  
• Suicidal ideation (not resulting in death) 
• Healthcare utilization including ED visits and hospi[INVESTIGATOR_411054], and those established practices will be followed per standard of care in 
each community.  When a medical or psychiatric emergency is identified, including presence of 
potential suicidal ideation, research staff will activate local procedures to ensure participant safety.  
As there is no planned interaction between limited study participants and research staff post enrollment, research staff will not actively intervene when safety events are identified in limited 
study participants.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518473]   January 15, 20 20 
 
66 
 DATA MANAGEMENT AND PROCEDURES  
 Design and Development  
This protocol will utilize a centralized Data and Statistics Center (DSC) for all quantitative data 
collected in the project . Qualitative data will be managed and stored by [CONTACT_144593], as 
described in Section 10 .10. The DSC will be responsible for the development of the CRFs, 
development and validation of the clinical study database, ensuring data integrity, and training 
site and participating node staff on applicable data management procedures. Advantage eClinical, 
a web- based distributed data entry system, will be implemented. This system will be developed 
to ensure that guidelines and regulations surrounding the use of computerized systems used in clinical trials are upheld. The remainder of this section provides an overview of the data management plan associated with this protocol.  
 Site Responsibilities 
The data management responsibilities of each individual site will be specified by [CONTACT_411119]’s Guide. 
 Data Center Responsibilities  
The DSC will 1) develop a data management plan and will conduct data management activities 
in accordance with that plan, 2) provide final guided source documents and eCRFs for the 
collectio n of all data required by [CONTACT_1758], 3) develop data dictionaries for each eCRF that will 
comprehensively define each data element, 4) conduct ongoing data monitoring activities on 
study data from all participating sites, 5) monitor any preliminary analysis data cleaning activities as needed, and 6) rigorously monitor final study data cleaning.  
 Data Collection  
Data will be collected at the study sites either on source documents, which will be entered at the 
site into eCRFs, or via direct entry into the eCRF. eCRFs are to be completed on an ongoing basis during the study. In the event that Advantage eClinical is not available, the DSC will provide 
the sites with paper guided source documents and completion instructions. Data entry into 
Advantage eClinical should be completed according to the instructions provided and project 
specific training. The investigator is responsible for maintaining accurate, complete and up- to-
date records, and for ensuring the completion of the eCRFs for each research participant.  
 Data Acquisition and Entry  
Completed forms and electronic data will be entered into the Advantage eClinical system in accordance with the Advantage eClinical User’s Guide, the CRF Instructions Manual and relevant 
instructions in the study operations manual. Only authorized individuals shall have access to 
eCRFs . 
 Data Editing  
Completed data will be entered into Advantage eClinical. If incomplete or inaccurate data are 
found, a query will be generated to the sites for a response. Sites will resolve data inconsi stencies 
and errors and enter all corrections and changes into Advantage eClinical.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518474]   January 15, 20 20 
 
67 
 Data Transfer/Lock  
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored at the DSC. This will not include the participant’s 
contact [CONTACT_1290]. Rather, individual participants and their research data will be 
identified by a unique study identification number. The study data entry and study management 
systems used by [CONTACT_200888]. Data will 
be transmitted by [CONTACT_268654]. The DSC 
will conduct final data quality assurance checks and “lock” the study database from furthe r 
modification. The final analysis dataset will be returned to NIDA, as requested, for storage and 
archive.  
 Data Training  
The training plan for research staff will include provisions for training on assessments, eCRF 
completion guidelines, data management procedures, and the use of Advantage eClinical.  
 Data Quality Assurance  
To address the issue of data entry quality, the DSC will follow a standard data monitoring plan. An acceptable quality level prior to study lock or closeout will be established as a part of the data 
management plan. Data quality summaries will be made available during the course of the 
protocol.  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518475]   January 15, 20 20 
 
69 
 PROTOCOL SIGNATURE [CONTACT_268659]’S REPRESENTATIVE (CCTN SCIENTIFIC OFFICER OR DESIGNEE)  
     
          
Printed Name   [CONTACT_360335] [CONTACT_9929]:  
• I am in receipt of version 2.[ADDRESS_518476] this clinical study in 
accordance with the design and provisions specified therein.  
• I agree to follow the protocol as written except in cases where necessary to protect the 
safety, rights, or welfare of a participant, an alteration is required, and the sponsor and IRB have been notified prior to the action.  
• I will ensure that the requirements relating to obtaining informed consent and institutional review board (IRB) review and approval in 45 CFR 46 are met.  
• I agree to personally conduct or supervise this investigation at this site and to ensure that all site staff assisting in the conduct of this study are adequately and appropriately trained 
to implement this version of the protocol and that they are qualified to meet the 
responsibilities to which they have been assigned.  
• I agree to comply with all the applicable federal, state, and local regulations regarding the obligations of clinical investigators as required by [CONTACT_9930] (DHHS), th e state, and the IRB.  
 
SITE’S PRINCIPAL INVESTIGATOR  
          
[INVESTIGATOR_411055]-0079-A1  Version 2.[ADDRESS_518477]   January 15, 20 20 
 
70 
 REFERENCES  
1. Centers for Disease Control. Opi[INVESTIGATOR_411056].  Vital 
Signs 2018  [cited 2018 May 20 ]; Available from: https://www.cdc.gov/vitalsigns/opi[INVESTIGATOR_2480] -
overdoses/index.html . Page  
2. Larochelle, M.R., et al., Medication for Opi[INVESTIGATOR_268555]: A Cohort Study.  Ann Intern Med, 2018. 169(3): 
p. 137 -145. 
3. D'Onofrio, G., et al., Emergency department -initiated buprenorphine/naloxone treatment 
for opi[INVESTIGATOR_2561]: a randomized clinical trial.  JAMA 2 015. 313(16): p. 1636- 44. 
4. Busch, S.H., et al., Cost -effectiveness of emergency department -initiated treatment for 
opi[INVESTIGATOR_2561].  Addiction, 2017. 112(11): p. 2002- 2010.  
5. D'Onofrio, G., R.P. McCormack, and K. Hawk, Emergency Departments - A 24/7/365 
Option for Combating the Opi[INVESTIGATOR_140701].  N Engl J Med, 2018. 379(26): p. 2487- 2490.  
6. Curran, G.M., et al., Effectiveness- implementation hybrid designs: combining elements of 
clinical effectiveness and implementation research to enhance public health impact.  Med 
Care, 2012. 50 (3): p. 217- 26. 
7. Rogers, E.M., Diffusion of Innovations . 5 ed. 2003, [LOCATION_001]: Free Press.  
8. Glasgow, R.E., T.M. Vogt, and S.M. Boles, Evaluating the public health impact of health 
promotion interventions: the RE -AIM framework.  Am J Public Health, 1999. 89(9): p. 1322-
7. 
9. Gaglio, B., J.A. Shoup, and R.E. Glasgow, The RE -AIM framework: a systematic review 
of use over time.  Am J Public Health, 2013. 103(6): p. e38- 46. 
10. Kessler, R.S., et al., What does it mean to "employ" the RE -AIM model? Eval Health Prof, 
2013. 36(1): p. 44 -66. 
11. Stiles, P.G., Boothroyd, R.A,. Ethical Use of Administrative Data for Research Purposes . 
2012 [cited 2019 April 12]; Available from: https://www.aisp.u penn.edu/wp  
content/uploads/2015/09/0033_12_SP2_Ethical_Admin_Data_001.pdf.  . 
12. Kunn, S., The challenges of linking survey and administrative data.  IZA World of Labor, 
2015. 214. 
13. Kirchner, J.E., et al., Outcomes of a partnered facilitation strategy to implement primary 
care- mental health.  J Gen Intern Med, 2014. [ADDRESS_518478] 4 : p. [ADDRESS_518479], and E.H. Bradley, Qualitative and mixed methods provide 
unique contributions to outcomes research.  Circulation, 2009. 119(10): p. 1442- 52. 
15. Beebe, J., Rapid assessment process , in The encyclopedia of social measurement , K. 
Kempf -Leonard, Editor. 2005. p. [ADDRESS_518480] of a masked alcohol screening 
questionnaire.  Alcoh ol Alcohol, 1991. 26 (1): p. 81 -91. 
17. Fleming, M.F., et al., Informed consent, deception, and the use of disguised alcohol 
questionnaires.  Am J Drug Alcohol Abuse, 1989. 15(3): p. [ADDRESS_518481]   January 15, 20 20 
 
71 18. Ali, R., et al., Ultra -rapid screening for substance- use disorders: the Alcohol, Smoking and 
Substance Involvement Screening Test (ASSIST- Lite).  Drug Alcohol Depend, 2013. 
132(1 -2): p. 352- 61. 
19. Cella, D., et al., The Patient -Reported Outcomes Measurement Information System 
(PROMIS) developed and tested its first wave of adult self -reported health outcome item 
banks: 2005 -2008.  J Clin Epi[INVESTIGATOR_5541], 2010. 63 (11): p. 1179 -94. 
20. HealthMeasures. PROMIS® (Patient ‐Reported Outcomes Measurement Information  
System).  2019 Aug 15, 2019]; Available from: http://www.healthmeasures.net/explore ‐
measurement ‐systems/promis. 
21. EuroQol. EQ ‐5D. 2019 Aug 15, 2019]; Available from: https://euroqol.org/ . 
22. Health Utilities Inc. Health ‐Related Quality ‐of‐Life. 2019  Aug 15, 2019]; Available from: 
http://www.healthutilities.com . 
23. Optum. SF Health Surveys.  [ADDRESS_518482] 15, 2019.]; Available from: 
https://www.optum.com/solutions/life ‐sciences/answerresearch/patient‐ insights/sf ‐health‐
surveys.html . 
24. Kaplan, R.M., et al., The Quality of Well- being Scale. Applications in AIDS, cystic fibrosis, 
and arthritis.  Med Care, 1989. 27([ADDRESS_518483]) : p. S27 -43. 
25. Hanmer, J., et al., Cross -sectional validation of the PROMIS -Preference scoring system.  
PLoS One, 2018. 13 (7): p. e0201093.  
26. Hanmer, J., et al., Selection of key health domains from PROMIS((R)) for a generic 
preference- based scoring system.  Qual Life Res, 2017. 26(12): p. 3377- 3385.  
27. Dewitt, B., et al., Estimation of a Preference -Based Summary Score for the Patient -
Reported Outcomes Measurement Information System: The PROMIS((R)) -Preference 
(PROPr) Scoring System.  Med Decis Making, 2018. 38 (6): p. 683 -698. 
28. Sobell, L.C., et al., Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations.  Br J Addict, 
1988. 83(4): p. 393 -402. 
29. Hsieh, H.F. and S.E. Shannon, Three approaches to qualitative content analysis.  Qual 
Health Res, 2005. 15(9): p. 1277- 88. 
30. Stiles, P.G., Boothroyd, R.A., Robst, J. & Ray, J.V.,, Ethically using administrative data in research: Medicaid administrators current practices and best practices recommendations.  
Administration & Society, 2011. 43: p. 171- 192. 
31. The CERT Coordination Center Homepage. [cited 2019; Available from: www.cert.org
. 
32. Insititute., S. The SANS Institute Homepage.  2019; Available from: www.sans.org . 
 
  
NIDA CTN-0079-A1  Version 2.[ADDRESS_518484]   January 15, 20 20 
 
72 
 APPENDIX A: DATA AND SAFETY MONITORING PLAN  
1.0 BRIEF STUDY OVERVIEW  
CTN -0079- A1 will evaluate the extent of diffusion and the sustainability of the Emergency 
Department ( ED)-initiated buprenorphine ( BUP ) clinical programs  (inclusive of opi[INVESTIGATOR_2428] [ OUD] screening, BUP treatment initiation, and referral for treatment)  introduced at 
each of the three clinical sites in the parent CTN -0079 study in furtherance of our original 
overarching research question:  In settings with high need, limited resources, and differing 
staffing structures for managing OUD, what is the feas ibility and impact of introducing a 
clinical protocol for OUD screening and BUP treatment initiation in the ED with referral for 
treatment? CTN-0079- A1 (the “ancillary study”)  is an implementation study that will use 
mixed methods and triangulate multiple sources of data to evaluate the feasibility, acceptability, 
sustainability, and impact of the ED- initiated BUP clinical program and implementation facilitation 
strategy and id entify factors influencing diffusion and effectiveness.   
PRIMARY AIMS  
1. Program Implementation  (Evaluation of Clinical Program Reach) : Over the course of 
the CTN -0079- A1 study, to estimate the proportion of  patients  receiving  (i) ED -
initiated/expedited BUP ( primary analysis) and (ii) ED-initiated  BUP  (secondary 
analysis) amongst ED patients who are candidates for ED -initiated BUP . The 
composite ED -initiated/ expedited measure will be analyzed primarily; ED -initiated 
BUP will be evaluated secondarily.  
2. Program  Effectiveness : Amongst participants who received ED -initiated/expedited 
BUP  over the course of the CTN -0079 -A1 study , to estimate the proportion of 
participants : (i) with confirmed linkage to formal addiction treatment   for OUD within 
one week  following E D discharge , and ( ii) who are confirmed to be engaged in formal 
addiction  treatment for OUD on the 30th day following ED discharge . Engagement in 
treatment on day 30 will be analyzed primarily; linkage will be evaluated secondarily.  
Other Aims : We will als o conduct several secondary implementation and effectiveness analyses 
as well as tertiary and exploratory analyses that include periods within the parent and ancillary studies and comparing available sources of data to further develop quality measures.   
SOURCES OF DATA  
1. Health record, administrative, claims, and registry data 
2. Research assessments involving ED patients who are candidates for ED-initiated BUP for 
OUD; these assessments will document the index ED visit through the 30th day after the 
index ED visit  
3. Qualitative data (qualitative interviews, focus groups, field notes) involving ED staff, ED 
patients, and other stakeholders and key informants  
4. Data collected through the CTN-0079 “parent” study  
5. Qualitative data collected through CTN- 0069  
As in CTN-0 079 (the “parent study”), all clinical care  (BUP and referral) will be delivered as part 
of each facility’s  clinical protocol, rather than as a research procedure.  Implementation Facilitation 
(IF) activities will continue during ancillary trial preparation  with a more intensive “booster” of IF 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518485] month prior to trial commencement. Thereafter, all study IF support 
will cease and ancillary study data collection will begin. Data collection will occur over  a course of 
approximately  12 months , divided into  two 6-month study periods  – the Post-IF and Maintenance 
Periods. In accordance with the RE-AIM framework  (Reach, Effectiveness, Adoption, 
Implementation, Maintenance), at minimum, a period of at least [ADDRESS_518486] been adapted from those used in the parent study to incorporate lessons learned. Thus, primary outcome analyses will use data from the ancillary 
study alone. Tertiary and exploratory analyses will incorporate data from the 6 -month period of 
patient enrollment of the parent study – that i s, the IF Period – as well as  data derived from linkage 
to administrative databases extending over a longer timeframe (from one year prior to 
patient/participants’ ED visit to two years following the ED visit/ enrollment).  
ED patients who are candidates for  ED-initiated BUP (and who meet the additional study eligibility 
criteria to become research participants) may be enrolled as Full Study or Limited Study 
participants. Full S tudy participation involves two in- person research visits  occurring ideally at the  
index ED visit and 30  days after ED discharge, as in the parent study. In addition, consenting 
participants will be asked to authorize study staff to perform a data match with health and 
administrative data pending data use agreements for a period beginning 1 year prior to enrollment 
and ending 2 years following study enrollment . Limite d Study participation will be offered to 
candidates who meet criteria for ED -BUP candidacy but do not meet all of the eligibility criteria 
(e.g., inadequate locator information) for F ull Study participation. Limited S tudy participation 
includes  completion of screening assessments and data matching only, without active 
participation in the baseline and day 30 research visits . In addition, a Waiver of Consent/HIPAA 
Authorization is requested to perform data matching for all adult ED patients who screen positive for non- medical opi[INVESTIGATOR_411000]. Analyses will also be 
conducted for subgroups, including those determined to be candidates for BUP and/or receive medication for OUD, among others.  
In addition, we will recruit ED staff, patients, and other stakeholders  and key informants to be 
participants in qualitative interviews and/or focus groups  at the close of study for the purpose of 
learning about patient -, provider -, and organizational -level barriers and facilitators to adoption and 
sustainability. These data (along with qualitative data collected through CTN -0069 and CTN -
0079) will provide context to study outcomes and allow us to more comprehensively address our primary research question.  
2.0 OVERSIGHT OF CLINICAL RESPONSIBILITIES  
A. Site Principal Investigator  
[INVESTIGATOR_9842]’s Principal Investigator (PI) is responsible for study oversight, including ensuring human research subject protection by [CONTACT_9939], trained research staff to assess, report, and monitor safety  events.  
Because this prospective study will examine BUP initiation, and the use of this medication is in 
line with community practice, safety reporting will be limited to recording opi[INVESTIGATOR_411048]- fatal overdose 
events, healthcare utilization including ED visits and hospi [INVESTIGATOR_602] , suicidal ideation, and all 
deaths including fatal overdoses will be tracked within the [ADDRESS_518487]   January 15, 20 20 
 
74 provided consistent with community practice, a medication adverse event profile will not be 
maintained.  
Non-fatal opi[INVESTIGATOR_411057] t he study  and collected on the 
Overdose Events and Risk Factors form . Safety events resulting in death including fatal 
overdoses  are required to be entered into the adverse/serious adverse event form set in the data 
system within 24 hours of site's knowledg e of the event. The other safety events will be reported 
on study specific forms.  
B. CCC Safety Monitor/Medical Monitor  
The NIDA CTN Clinical Coordinating Center’s (CCC) Safety Monitor/Medical Monitor or designee 
is responsible for reviewing all adverse events and serious adverse events reported. The CCC 
Safety Monitor/Medical Monitor is alerted via email each time an SAE is reported in the EDC. All SAEs will be reviewed at the time they are reported in the EDC . The Safety Monitor/Medical 
Monitor or designee will also indicate concurrence or not with the details of the report provided by [CONTACT_7880]. Where further information is needed, the Safety Monitor/Medical Monitor or designee 
will discuss the event with the site staff.  Reviews of SAEs by [CONTACT_200893]/Medical 
Monitor or designee will be documented in the Advantage eClinical data system and will be a part of the safety database. All AEs are reviewed on a weekly basis to observe trends or unusual 
events.  
Voluntary Regulatory Reporting in non- IND T rials:  
For non- IND trials, if an event meets expedited reporting criteria (serious, related and unexpected) 
the CCC Safety Monitor/Medical Monitor or designee will voluntarily report to FDA/Regulatory 
Authorities using the MedWatch Form [ADDRESS_518488] (D SMB ) 
The NIDA CTN Data and Safety Monitoring Board ( DSMB ) affiliated with this trial will be 
responsible for conducting periodic reviews of accumulating safety, trial performance, and 
outcome data. Reports will be generated and presented for DSMB meetings. The DSMB will make 
recommendations to NIDA CCTN as to whether there is sufficient support for continuation of the 
trial, evidence that study procedures should be changed, or evidence that the trial (or a specifi c 
site) should be halted for reasons relating to safety of the study participants or inadequate trial 
performance (e.g., poor recruitment).  
Following each DSMB meeting, the NIDA CCTN will communicate the outcomes of the meeting, based on DSMB recommendations, in writing to the study Lead Investigator. This communication 
summarizing study safety information will be submitted to participating IRBs.  
D. Quality Assurance (Q A) Monitoring  
The monitoring of the study site(s) will be conducted on a regular basis using a combination of 
NIDA CCTN CCC monitors and the local Node QA Monitors . Investigators will host periodic visits 
for the NIDA CCTN CCC monitors and local Node QA Monitors . The purpose of these visits is to 
assess compliance with the protocol, GCP requirements, and other applicable regulatory requirements, as well as to document the integrity of the trial progress . The investigative site will 
provide direct access to all trial related sites (e.g., research office), source data/documentation, and reports for the purpose of monitoring and auditing by [CONTACT_85231], as well as for inspection 
by [CONTACT_3482]. Areas of particular concern will be the review of inclusion/exclusion criteria, participant Informed Consent Forms, protocol adherence, s afety 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518489] participant identifiers on site, as well 
as secure computing procedures for entering and transferring electronic data. The documents or 
logs linking the study codes with the study participant on site will be kept locked/securely stored  
separately from the study files and the medical records. No identifying information will be disclosed in reports, publications or presentations.  
Information That Meets Reporting Requirements 
The consent form will specifically state the types of information that are required for reporting and 
that the information will be reported as required. These include suspected or known sexual or 
physical abuse of a child or elders, or threatened violence to self and/or others.  
Participant Protection  
This is a minimal risk observational study  
that will use mixed methods and triangulate multiple 
sources of data to evaluate the feasibility, acceptability, sustainability, and impact of the ED -
initiated BUP clinica l program and implementation facilitation strategy and identify factors 
influenc ing diffusion and effectiveness. Patients  will be evaluated for BUP administration as per 
local clinical guidelines.  
Pregnancy  
As there is no medication intervention, pregnancy  will not be followed within the context of this 
study . 
Recruitment Monitoring 
Participant recruitment and achievement of targets will be closely monitored on an ongoing basis 
throughout the duration of both data collection periods. Trial progress and data status reports 
(Section 19.9) will be reviewed frequently (e.g., daily ) by [CONTACT_411120] (e.g., 
weekly ) with the Lead Team. These reports will provide information on numbers screened and 
enrolled (by [CONTACT_411121]), time and day of week of ED presentation, and numbers of enrolled 
participants receiving buprenorphine. This information will be used continuously throughout 
enrollment to inform recruitment shifts , staffing, and the need for additional training and support. 
All sites will be required to prepare a site -specific local SOP outlining recruitment procedures and 
a contingency plan should enrollment rates fall below target in any given month. After the first 
NIDA CTN-0079-A1  Version 2.[ADDRESS_518490]   January 15, 20 20 
 
76 three months of active recruitment (halfway through the Post -IF period) the Lead Team will have 
a formal review to identify recruitment trends and address any issues that arise.  
3.0 DATA MANAGEMENT PROCEDURES  
This protocol will utilize a centralized Data and Statistics Center (DSC)  for all quantitative data. A 
web-based distributed data entry model will be implemented. This electronic data capture system 
(Advantage eClinical) will be developed to ensure that guidelines and regulations surrounding the 
use of computerized systems in clinical trials are upheld.  All qualitative data will be stored on a 
password protected, encrypted university owned and secured com puter.  
4.0 DATA AND STATISTICS CENTER RESPONSIBILITIES  
The DSC will: 1) develop and apply data management procedures to ensure the collection of 
accurate and good- quality data, 2) provide source documents and electronic Case Report Forms 
(eCRFs) for the collection of all data required by [CONTACT_1758], 3) develop data dictionaries for each 
eCRF that will comprehensively define each data element, 4) prepare instructions for the use of Advantage eClinical and for the completion of eCRFs, 5) conduct ongoing monitoring activities on 
study data collected from all participating sites, and 6) perform data cleaning activities prior to the final study database lock.  
5.[ADDRESS_518491] entry into the eCRF. In the event that 
Advantage eClinical is not available, the DSC will provide the sites with a final set of guided source 
documents and completion instructions. Data will be entered into Advantage eClinical in accordance with the instructions provided during protocol -specific training and guidelines 
established by [CONTACT_9928]. Data entry into the eCRFs is performed by [CONTACT_4539]. Selected source documents and eCRFs may also require the investigator’s signature (wet or 
electronic). In some situations, data collected on source documents will not be entered into 
Advantage eClinical, but when it is entered, it will follow the guidelines stated above.   
The Principal Investigator [INVESTIGATOR_200785], complete and up -to-
date research records. In addition, the Principal Investigator [INVESTIGATOR_411058]. Audio recordings will be obtained using an 
encrypted recorder and transcribed by a professional HIPAA compliant transcription service. 
Research staff, with oversight by [CONTACT_7880], is responsible for maintaining accurate, complete 
and up- to-date research records. T he site PI  [INVESTIGATOR_411059].  
6.[ADDRESS_518492]   January 15, 20 20 
 
77 Trial progress and data status reports, which provide information on recruitment, availability of 
primary outcome, attendance at follow -up visits, regulatory status, and data quality, will be 
generated daily and posted to a secure website. These reports are available to the site, the corresponding Node, the Lead Investigator, the coordinating centers, and NIDA CCTN, to monitor 
the sites’ progress on the study.  
7.0 DATABASE LOCK AND TRANSFER  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the DSC. Individual participants and their research 
data will be identified by a unique study identification number; further, some identifiable data may 
be collected in eClinical. The study data entry and study management systems used by [CONTACT_200895].  
At the conclusion of data collection for the study, the DSC will perform final data cleaning activities 
and will “lock” the study database from further modification. The final raw dataset will be 
transferred to the Lead Investigator or designee. De- identified versions of these datasets will also 
be provided to the NIDA CCTN- designated part y for storage and arc hiving. These datasets maybe 
be posted on the NIDA Data Share website. 
Reference: http://grants.nih.gov/grants/guide/notice- files/not98- 084.html
  
 